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Telomeres are nucleoprotein complexes that cap the ends of linear 
chromosomes and preserve genomic integrity.  They help overcome two biological 
problems posed by linear chromosomes. The first problem, called the end protection 
problem, is solved by the shelterin complex. Shelterin is the six-protein complex that 
forms the major protein constituent of telomeres, coating telomeric DNA to protect 
chromosome ends from being misrecognized by the DNA damage response and repair 
machineries. The shelterin component TPP1 also helps solve the second problem 
associated with linear chromosomes called the end replication problem, which arises 
because replicative polymerases cannot fully synthesize DNA at chromosome ends. 
TPP1 recruits the ribonucleoprotein (RNP) enzyme telomerase to telomeres, where it 
compensates for telomere attrition by addition of telomeric repeats, thereby enabling 
continued cell division in stem and germ line cells. The lack of telomerase in most 
somatic cells limits their unregulated division. However telomerase is upregulated in 
~90% of cancers, qualifying it as an attractive target for anti-cancer drug design.  
Mutations in telomere and telomerase associated genes can lead to a variety of 
telomeropathies, the most prominent of which is an inherited bone marrow failure 
syndrome called dyskeratosis congenita (DC). As a consequence of these mutations, 
patients with DC have extremely short telomeres. Our lab was involved in characterizing 
DC in a patient who was heterozygous for an in frame deletion of lysine 170 (K170) in 
the shelterin protein TPP1. Although K170 is found near a region of residues in TPP1 
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responsible for recruiting telomerase, referred to as the TEL patch, this residue was not 
identified in previous screens.  Here, using a combination of biochemistry and cell 
biology, we demonstrate that this mutation causes a defect in the ability of TPP1 to 
recruit telomerase or stimulate its repeat addition processivity, and affects its ability to 
maintain telomere length in vivo. Using X-ray crystallography, I illustrate that TPP1 
K170Δ alters the TEL patch, spatially displacing two critical glutamates. Finally, we use 
CRISPR-Cas9 gene editing to show that introducing this mutation in a heterozygous 
context is sufficient to cause telomere shortening in human cells, thereby providing 
important insights into the genetics of DC.  
While the surface on TPP1 that is responsible for telomerase recruitment has 
been well characterized, it is not as clear which regions of the protein subunit of 
telomerase (TERT) are important for this interaction. The TEN domain and the IFD of 
TERT have been implicated in TPP1 binding, although only one specific interaction 
between the TEN domain and the TEL patch has been identified. Here, I use an alanine 
scanning mutagenesis screen in conjunction with an in-cell recruitment assay to identify 
one region each in the TEN domain and IFD that contain residues necessary for 
telomerase recruitment to the telomere. These mutations showed wild-type telomerase 
RNP assembly but hindered TPP1-stimulated telomerase activity in vitro and adversely 
affected the extension of telomeres by telomerase in cultured cells. In summary, my 
studies have helped pinpoint the TERT side the TPP1-telomerase interface that is 
critical for both cancer cell proliferation and normal stem cell function. 
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 Eukaryotic chromosomes are linear and end in nucleoprotein complexes called 
telomeres. Telomeric DNA is composed of a repetitive sequence (GGTTAG/CCAATC in 
humans) that is largely double-stranded (ds; 10-15 kb in humans), but ends in a short 
single-stranded (ss; 50-500 nt in humans) G-rich 3’ overhang [1]. Linear chromosomes 
present two major biological hurdles at chromosome ends: the end replication and end 
protection problems. The end protection problem occurs when the natural ends of linear 
chromosomes are misrecognized by the DNA damage response and repair machinery 
as double strand breaks requiring repair [1]. The six-protein complex shelterin, 
consisting of proteins POT1, TPP1, TIN2, TRF1, TRF2, and Rap1, solves the end 
protection problem by coating telomeric DNA (Figure 1.1) [1-12]. While TRF1 and TRF2 
recognize ds telomeric DNA, POT1 binds the ss overhang with high specificity and 
affinity [5,13]. By coating telomeric DNA, the shelterin complex sequesters it away from 
the ATM and ATR mediated DNA damage response pathways [1,14]. Although linear 
chromosomes must be protected from the DNA damage response machinery, they must 
                                            
1
 A modified version of this chapter comes from a review titled “The structural biology of chromosome end 
maintenance”  that is in submission to Cellular and Molecular Life Sciences written by Devon Pendlebury, 
Jayakrishnan Nandakumar and myself. I wrote all sections that appear here with input and comments 
from Jayakrishnan Nandakumar. 
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also allow recruitment of telomerase to those ends to solve the second problem 
associated with linear chromosomes called the end replication problem. 
Telomerase, a ribonucleoprotein enzyme is able to solve the end replication 
problem by adding telomeric repeats to the extreme ends of linear chromosomes 
helping to maintain telomere length over time. The action of telomerase is essential for 
the continued division of stem and germ line cells. Telomerase conducts this function 
with the help of a core protein component called Telomerase Reverse Transcriptase 
(TERT), which amongst many features contains a catalytic reverse transcriptase 
domain for DNA synthesis [15-17].   Telomerase also contains an RNA subunit called  
Telomerase RNA component (TERC or TR) which harbors the template for the 
synthesis of telomeric repeats at the extreme 3’ end of the chromosome  [18,19]. 
Telomerase counteracts DNA attrition that would normally be observed due to the end 
replication problem by synthesizing several telomeric repeats at chromosome ends 
(Figure 1.1) [20]. 
Telomerase is expressed in both germ line and stem cells to facilitate their 
continued cell division [21]. It is therefore not surprising that mutations in telomere- and 
telomerase-associated genes result in inherited stem cell-dysfunction diseases 
collectively known as “telomeropathies”, the most notable of which is dyskeratosis 
congenita or DC [22,14,23]. Normally nondividing cells lacking telomerase enter a non-
proliferative state called senescence once their telomere length falls below a certain 
threshold [24]. This is an anti-tumorigenic mechanism to prevent uncontrolled cell 
division. However if a rare cell escapes senescence and aberrantly resumes telomerase 
expression to re-establish telomere length maintenance, it could attain “replicative 
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immortality”, a hallmark of cancer [25,26]. In fact an overwhelming majority of cancers 
(~90%) show telomerase expression [27,28], and thus this enzyme is a promising target 
for anti-cancer drug discovery.  
1.2 Double stranded end protection 
Telomeric DNA is both double stranded and single stranded and must be 
protected from being misrecognized as a DNA lesion by DNA damage response and 
repair machinery. Two shelterin components, TRF1 and TRF2 bind the double stranded 
region of telomeric DNA, protecting it from erroneous DNA damage responses (Figure 
1.1) [3,29]. Both proteins have a C-terminal myb domain that binds in a sequence 
specific manner to the major groove of ds telomeric DNA (Figure 1.2) [30-33]. TRF2 is 
able to use this feature to block the ATM mediated DNA damage response (Figure 1.1) 
[5,1,34-36]. TRF2 also facilitates the formation of T-loops, specialized telomeric DNA 
conformations in which the 3’ end of the telomere invades the double stranded region of 
telomeric DNA, potentially providing an additional mechanism to protect chromosome 
ends [37-39]. Both TRF2 and TRF1 also contain a TRF homology domain (TRFH) which 
simultaneously facilitates the homodimerization of TRF1 and TRF2, while also 
preventing their heterodimerization [40]. Beyond dimerization the TRFH domain allows 
both TRF1 and TRF2 to recruit specific accessory proteins to the telomere. TRF1 
interacts with proteins that contain an F-X-L-X-P motif (where X can be any amino acid), 
the most notable of which is the shelterin protein TIN2. TRF2 has a preference for 
binding proteins containing a Y-X-L-X-P motif, examples of which include the nuclease 
Apollo/SNM1B and the DNA damage response protein NBS1 [41]. Outside of the TRFH 
domain, TRF2 also interacts with shelterin component Rap1, which functions in 
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repressing homology directed repair (HDR) [42,43]. While the ability to directly protect 
ds telomeric DNA is vital; TRF1 and TRF2 have a second major role at the telomere, 
which is the recruitment of the rest of shelterin (RAP1, TIN2, TPP1, and POT1) for 
faithful end protection and end replication (Figure 1.1). The importance of these proteins 
is highlighted by the fact that knocking out either TRF1 or TRF2 causes embryonic 
lethality in mice [44,45].   
1.3 Single stranded end protection 
The very end of any eukaryotic chromosome is single-stranded and thus a 
potential substrate for illicit homology-driven recombination or repair. Thus a major 
challenge in end protection involves preventing this DNA from participating in such 
processes. The G-rich 3’ ss overhang of telomeric DNA is also involved in end 
replication as it provides the site for telomerase to bind and extend chromosomes. Both 
of these functions are either directly dictated by (in case of end protection) or facilitated 
by (in case of end replication) proteins that bind the ss overhang. 
1.3.1 Ciliates provide the first insights 
The first major structural insights into G-rich 3’ ss DNA-binding proteins came 
from the structure of the Sterkiella nova (S. nova; formerly Oxytricha nova) proteins 
TEBP-α and TEBP-β, which bind as a heterodimer to ss DNA at chromosome ends (left; 
Figure 1.3A) [46,47]. The TEBP-α protein is composed of three 
oligosaccharide/oligonucleotide binding (OB) domains. The two N-terminal OB domains 
collectively form a DNA-binding domain (DBD) that binds specifically to the 3’ ss 
overhang of the telomeric DNA. [47,48]. The protein-DNA interface is formed between 
residues on both TEBP-α and β, and the bases and deoxyribose groups of the DNA. 
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Thus, this interface is rich in hydrogen bonding, hydrophobic, and pi-stacking 
interactions. In fact almost every base in the protein-DNA co-crystal structure stacks 
with an aromatic amino acid or another base. Following the track that the DNA takes 
through the structure reveals that the 3’ end interacts not only with TEBP-α, but also 
several residues in TEBP-β (left; Figure 1.3A). The terminal 3’ nucleotide G11 folds 
back to stack with nucleotide T7 burying the extreme end of the chromosome within the 
protein-DNA complex (left; Figure 1.3A). Because of these extensive interactions, the 
TEBP-α and TEBP-β heterodimer is able to protect the ss tail of the telomere from 
potential interactions with DNA damage response proteins. Although this structure 
provides a compelling solution to the end protection problem, it is likely that the TEBP-α-
β-DNA complex undergoes a conformational change to allow telomerase to access to 
extend the chromosome ends. 
1.3.2 Protection of ss DNA at chromosome ends by human POT1-TPP1 
 Human telomeres are longer than that of S. nova and are composed of more 
proteins, but they still must overcome the same biological hurdles. The protein that 
protects the ss overhang at human chromosome ends is called POT1 (Figure 1.1, 1.3), 
a homolog of which also exists in Schizosaccharomyces pombe (S. pombe) [7]. Not 
surprisingly, both S. pombe and human POT1 have a similar overall structure to that of 
S. nova TEBP-α [49,13]. The DNA binding domain (DBD) of human POT1 uses two N-
terminal OB domains (OB1 and OB2) to bind to the ss overhang of telomeric DNA (right; 
Figure 1.3A). A crystal structure of this complex details how the OB1 of POT1 is able to 
interact with the first six bases of the 10 nt telomeric sequence (1-TTAGGG-6) (left; 
Figure 1.3B) in a fashion similar to that of the homologous S. pombe POT1pN protein 
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fragment (not shown). Both structures detail stacking interactions between aromatic 
residues in POT1 and the bases of the telomeric DNA. In addition to these stacking 
interactions, OB1 makes several hydrogen bonds with the telomeric DNA. OB2 of 
human POT1 makes less extensive hydrogen bonds with telomeric DNA, but the four 3’ 
bases in the crystal structure (7-TTAG-10) all stack with aromatic residues present on 
OB2 (right; Figure 1.3B). Interestingly, OB2 of S. pombe Pot1 exhibits lower sequence 
specificity compared to the adjacent OB1 domain and binds optimally to a 9-mer DNA 
sequence [50]. Although the overall structure of human POT1’s DBD is very similar to 
that of TEBP-α’s DBD, the track of the DNA through the two OB domains in these 
structures is strikingly different (Figure 1.3C). In POT1 the DNA is kinked as it passes 
from OB1 to OB2. This occurs because the two OB domains in the POT1 structure are 
oriented differently relative to one another than they are in the S. nova structure (Figure 
1.3A). Additionally the 3’ end of the DNA does not curve back towards POT1 as it does 
in the S. nova structure (Figure 1.3C). These differences may be attributed to the fact 
that the S. nova structure contains the full TEBP-α-β complex bound to DNA while the 
POT1-DNA structure lacks both TPP1 (mammalian TEBP-β homolog) and the TPP1-
binding domain of POT1.  Alternatively, these structural differences may suggest distinct 
species-specific solutions for end protection (see discussion of human POT1-TPP1-
DNA SAXS data below).  
The high affinity and specificity of POT1 for ss telomeric DNA provides an 
elegant mechanism for protection against an ATR kinase mediated response and 
subsequent homologous recombination (HR) at chromosome ends [49,51]. An essential 
initial step for HR is binding of the participating ss DNA with Replication protein A 
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(RPA), a heterotrimer composed largely of OB domains [52]. By binding ss telomeric 
DNA with high affinity and sequence specificity, POT1 blocks access of RPA to prevent 
ATR activation at chromosome ends (Figure 1.1) [53]. Indeed, mutations in the DNA-
binding domain of POT1 are associated with chromosome end aberrations including 
fusions in several chronic lymphocytic leukemias (CLL) and familial melanomas (FM), 
highlighting the importance of this protein in maintaining genome integrity [54,55]. 
1.3.3 POT1-TPP1 interface 
The first structural insights into how the POT1-TPP1 heterodimer forms to protect 
chromosome ends and to facilitate end replication came from analysis of the TEBP-α-β 
complex. TEBP-α has a third C-terminal OB domain that makes extensive interactions 
with a C-terminal region of TEBP-β that is partly helical but mostly extended in 
conformation (Figure 1.3A). However the C-terminus of POT1 does not share much 
sequence similarity with TEBP-α making it unclear if TPP1 and POT1 would interact in a 
similar manner. Two similar structures of the C-terminus of POT1 in complex with the 
POT1 binding domain (PBD) of TPP1 were solved using X-ray crystallography [56,57]. 
These structures revealed that the C-terminus of POT1, like TEBP-α, forms an OB 
domain that is able to make extensive interactions with TPP1 (Figure 1.4A). 
Unexpectedly, the authors also identified an additional TPP1-binding element within 
POT1: a Holliday junction resolvase like domain (HJRD) inserted within POT1’s third 
OB domain (OB3). In both structures the two α-helices and a 310 helix of TPP1’s PBD lie 
in grooves formed by the OB3 and the HJRD domains of POT1. Somatic mutations 
associated with several CLL and FL malignancies are mapped to the TPP1-binding 
region of POT1 [56,57]. This is not surprising, because the inability to bind TPP1 will 
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prevent recruitment of POT1 to telomeres, thereby unleashing chromosome end 
deprotection [53,58,59].  
 Although there is no high-resolution structure for the human POT1-TPP1-DNA 
complex, small-angle X-ray scattering (SAXS) analysis of the TPP1-N-POT1-DNA 
complex has revealed an elongated V shaped envelope. In the model generated with 
these data, TPP1 OB is proposed to be distal to both the DBD of POT1 and the 
telomeric DNA [56]. This is in stark contrast to the overall heart-shaped structure of 
TEBP-α-β-DNA that brings both subunits in close proximity and allows them to interact 
simultaneously with ss DNA. A high-resolution human POT1-TPP1-DNA structure will 
be instrumental to address the apparent differences in how ss DNA ends are protected 
in S. nova versus human.  
1.3.4 Hierarchical assembly of shelterin at telomeres 
POT1 is required for telomere maintenance, yet it cannot arrive at the 
chromosome end without being recruited by its binding partner TPP1  [58]. Before 
recruiting POT1, TPP1 must itself localize to telomeres with the help of the shelterin 
protein TIN2 [60,61]. TIN2 plays a central role at telomeres as it is able to bind TRF1, 
TRF2, and TPP1. TIN2 recruitment to telomeres requires binding to TRF1 [62]. 
Although binding to TRF2 is not mandatory for TIN2 recruitment to telomeres, it is 
important for stabilizing TRF2 protein for proper repression of ATM mediated damage 
response [63]. Due to the hierarchical nature of shelterin assembly, defects in TIN2 
recruitment or expression negatively impact TRF2, POT1, and TPP1 function. Indeed 
depletion of TIN2 results in the activation of both ATM and ATR DNA damage response 
pathways [62]. 
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1.4 Chromosome end replication 
The second problem associated with linear chromosomes is called the end 
replication problem. Maintenance of eukaryotic genomes is complicated due to the 
inability of replicative DNA polymerases to synthesize nucleotides at the extreme 3’ 
ends of linear chromosomes. Telomerase catalyzes the addition of telomeric repeats 
(TTAGGG sequence in mammals) to the ends of linear chromosomes (Figure 1.1A) 
[18,19,15,17]. In humans, telomerase adds ~50 nucleotides of telomeric DNA during 
every round of replication, which helps compensate for the attrition of DNA that occurs 
due to the end replication problem. This function is necessary to facilitate the continued 
division of stem and germ line cells and mutations in telomere and telomerase 
associated genes can lead to a variety of diseases called telomeropathies. 
1.4.1 The role of TPP1 in telomerase recruitment  
One major question that still eludes the field is how telomerase accesses a 
chromosome end that is so efficiently protected by POT1-TPP1. POT1-TPP1 plays a 
dual role at telomeres by stimulating telomerase activity and processivity while also 
protecting telomeric DNA [64]. POT1 tethers TPP1 close to the 3’ end, where TPP1 is 
able to directly recruit telomerase to the telomere using its N-terminal OB domain 
[60,64,65]. The crystal structure of the TPP1 OB domain illustrates a five-stranded β-
barrel that resembles the OB domain found in TEBP-β (Left; Figure 1.4B) [64]. Several 
independent studies led to the discovery of the TEL patch (TPP1 glutamate (E) and 
leucine (L)-rich patch) in TPP1 OB as a critical surface element for binding telomerase 
[66-68]. Three critical glutamate residues in the TEL patch (E168, E169, and E171) lie 
in a long flexible loop that protrudes from the β-barrel and ends in a short α-helix (right; 
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Figure 1.4B). In the asymmetric unit of the TPP1 OB crystal structure, TPP1 forms a 
non-physiological dimer using its largely hydrophobic N-terminal tail. This region, 
termed the NOB (N-terminus of the OB domain), is also involved in recruiting 
telomerase (right; Figure 1.4B) [69]. Although much has been uncovered about the 
surface of TPP1 that recruits telomerase, far less is known about the surface of 
telomerase that interacts with TPP1. To date, only one direct salt-bridging interaction is 
firmly mapped between human TPP1 and telomerase [70]. 
1.4.2 Telomerase RNA 
Although the length and sequence of telomerase RNA can vary widely between 
species, the RNA often contains three structurally conserved domains: the 
template/pseudoknot, the CR4/5 (STE) domain, and the H/ACA box (Figure 1.5A) 
[71,72]. The secondary structure conservation of these motifs highlights the essential 
role they play in telomerase function. The 5’ end of TR folds into a template-containing 
pseudoknot. The template is flanked by a 5’ template boundary element (TBE) and a 3’ 
template recognition element (TRE) (Figure 1.5A) [73-77].  The ss TRE helps TERT 
recognize and position the template in the active site of the enzyme to facilitate repeat 
addition processivity. The template boundary element (TBE) prevents the addition of 
nucleotides outside of the defined telomeric repeat. Telomerase is a processive 
enzyme, extending chromosome ends by adding multiple telomeric repeats per 
replication cycle. It is still unclear how the template is translocated to the end of the 
nascent terminal repeat to facilitate continued addition although a few models have 
been proposed. Single molecule FRET and biochemical experiments suggest an 
accordion model. In this model the TBE and template recognition element (TRE) 
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expand and contract to allow movement of the template during the catalytic cycle [78]. 
Another hypothesis is inspired by the mode of action of translesion DNA polymerase v. 
It suggests that after synthesis of a telomeric repeat, the GT-rich newly synthesized 
DNA loops out into a non-canonical hairpin, while the template translocates to pair with 
the AG at the 3’ end. Ultimately, an incoming dGTP allows the DNA to realign so 
another step of synthesis can proceed  [79].  Further biophysical and structural studies 
will be necessary to gain a better understanding of telomerase repeat addition 
processivity. Outside of the template the pseudoknot is formed by a series of helices 
and loops for which several structures from ciliates, yeast, and vertebrates exist [80,81]. 
Following the pseudoknot is the CR4/5 domain (SL4 region in Tetrahymena), 
which is the major TERT-binding domain within telomerase RNA (Figure 1.5A). 
Crosslinking studies [82] combined with the solved crystal structure of the CR4/5 
domain bound to the TRBD (Telomerase RNA binding domain) from the fish Oryzias 
latipes (medaka) [83] have provided atomic details of the interface between the core 
telomerase RNA and protein subunits that depends both on sequence and conformation 
of the RNA. The CR4/5 domain forms a three-way junction that takes on an L-shape 
(Figure 1.6A). Two stems, P6 and P6.1, of the CR4/5 domain directly interact with TERT 
by forming hydrogen bonds between their RNA backbone and residues on two separate 
TERT surfaces (Figure 1.6A) [83]. While the structure of the human CR4/5 domain 
remains unsolved, there is an NMR structure of human stem P6.1 that is structurally 
similar to that of Oryzias latipes (medaka), suggesting the human CR4/5 may interact 
with TERT in a similar manner [84].  
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TRBD forms the protein half of the interface between TERT and the CR4/5 of TR. 
Sequence conservation suggests TERT TRBDs from many organisms contain three 
motifs (CP, QFP, and T motifs) that are important for binding TR (Figure 1.5B). 
Vertebrate TRBDs have an additional vertebrate specific RNA binding motif (VSR) 
found on the N-terminal portion of the TRBD. All four of these motifs have been shown 
biochemically to take part in TR binding at some capacity [82,83,85]. Atomic details of 
this interface have been elucidated with the help of TRBD structures from Tetrahymena, 
medaka, and Tribolium castaneum. Each of these structures have been solved in 
complex with a TR fragment, while the structure of the TRBD from Takifugu rubripes 
(Japanese puffer fish) has been solved in apo form [83,85-89]. In all cases the TRBD is 
mostly helical with some globular portions with the differences in the structures residing 
mainly in the N-terminal linker region. 
 At the far 3’ end of the mature RNA lies the H/ACA domain. The H/ACA domain 
ensures TR stability by acting as a scaffold for proteins such as Dyskerin, GAR1, NHP2, 
and NOP10 (Figure 1.5A) [90-92]. One such element within the H/ACA domain is the 
CAB box which is responsible for binding the telomerase accessory protein TCAB1 and 
essential for Cajal body localization of telomerase [93-95]. TCAB1 can help stimulate 
telomerase activity through an interaction between its WD40 repeat domain and the 
CAB box of TR. This interaction stabilizes the CR4/5 domain so that it can interact with 
the TRBD of TERT creating an active form of telomerase [96]. The recent cryo-EM 
structure of human telomerase has provided the first structural information as to how the 
H/ACA domain interacts with dyskerin, GAR1, NHP2, NOP10, and TCAB1 (discussed 
further below) [97].  
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1.4.3 Telomerase Reverse Transcriptase (TERT) 
The second portion of the telomerase holoenzyme is the reverse transcriptase 
TERT. TERT is largely made up of four conserved domains: the telomerase essential N-
terminal domain (TEN), the TERT RNA binding domain (TRBD), the reverse 
transcriptase domain (RT), and the thumb domain also called C-terminal extension 
(CTE) (Figure 1.5B) [98]. Along with the cryo-EM structure of human telomerase, many 
studies have helped elucidate structural aspects of TERT in ciliates, yeast, and insects 
among other species. 
 One major focus of structural studies has been the essential TEN domain. 
Structural studies in Hansenula polymorpha  and Tetrahymena thermophila suggest that 
although the TEN domain sequence varies widely between species, the core structure 
is well conserved (Figure 1.6C and D) [99,100]. Although structural data for the human 
TEN domain is unavailable, functional data confirms it is essential for recruiting 
telomerase to telomeres. Mutations in the DAT (Dissociates Activities of Telomerase) 
region of the TEN domain render the enzyme unable to function in vivo, yet it retains 
catalytic activity in vitro (Figure 1.5B) [101]. Indeed in vivo telomerase function is 
rescued by linking the mutant telomerase to either POT1 or TRF2, further suggesting a 
role for the DAT region in telomerase recruitment to telomeres [102]. Three mutants in 
the DAT region (K78E, G100V, and R132E) of human telomerase have been implicated 
in reducing TPP1’s ability to stimulate processivity [70,103,104]. Charge-swap 
experiments suggest a direct interaction between residue K78 in the DAT region of the 
TEN domain and E215 in the TEL patch of TPP1 [70]. Although establishing this direct 
interaction was paramount towards building an understanding of telomerase 
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recruitment, much more remains to be learned regarding the remaining residues of the 
TEN domain and other regions of telomerase that interact with TPP1. TPP1’s OB 
domain, specifically the TEL patch and NOB regions, are essential for telomerase 
recruitment to telomeres (Figure 1.4B; right) [66,68,69]. Together these data strongly 
suggest a direct interaction between the TPP1 TEL patch or NOB region and the DAT 
region in the TEN domain of telomerase.  
The TEN domain has also been implicated in binding nucleic acids. HSQC NMR 
experiments involving primer DNA and template RNA, both alone and as hybrids, 
titrated with Hansenula polymorpha TEN domain revealed that the TEN domain was 
able to interact more specifically with DNA/RNA hybrids [100]. This supports the fact 
that the TEN domain helps facilitate recognition of the DNA-RNA template hybrid in the 
active site [105]. Additionally crosslinking data suggest that the TEN domain binds DNA 
in a fashion that would allow it to act as an anchor site 5’ to the template/DNA duplex 
[106,107]. The interaction between the TEN domain and DNA/RNA could help facilitate 
telomerase processivity by helping orient the primer/template hybrid for proper catalysis. 
The three subsequent domains make up the TERT ring (Figure 1.5B). The first of 
these is the TRBD which is responsible for interacting with the CR4/5 domain of TR 
forming the major interface between TERT and TR (discussed above). Structural 
information about the rest of the TERT catalytic subunit comes largely from crystal 
structures of the T. castaneum catalytic subunit (TcTERT; Figure 1.7A) and the human 
CTE domain (Figure 1.6B) [87,88,108]. Structures exist for both non-canonical RNA-
DNA hairpin-bound and apo TcTERT [87,88].  Both structures suggest that the catalytic 
core of the telomerase protein subunit is similar to that of retroviral reverse 
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transcriptases and viral RNA polymerases [87]. The structure is composed of an RT 
domain and a CTE, which together form a hand–like structure composed of fingers and 
palm domains in the RT, and a thumb domain represented by the CTE. Together the 
TRBD, fingers, palm, and thumb form a ring with a positively charged cavity where the 
RNA-DNA hairpin resides (Figure 1.7A). This TERT ring interacts with the RNA-DNA 
hairpin in a manner that orients the RNA template in the active site, generating a 
conformation that allows for the synthesis of additional nucleotides. To facilitate this, the 
5’ end of the RNA interacts with the fingers and palm regions while the thumb interacts 
with the minor groove formed by the RNA-DNA heteroduplex. A rigid loop in the thumb 
domain forms the primer grip region that directs the 3’ end of the DNA toward the active 
site of the protein.  The thumb domain is also in close contact with the TRBD and has 
been shown to interact with CR4/5 through an FVYL motif (Figure 1.5A) [109]. The 
FVYL motif was further shown to be important in both structural and biochemical studies 
of the human CTE, where dyskeratosis congenita-associated mutations have been 
found (Figure 1.6B) [108]. The fingers and CTE also contain residues that have been 
implicated in recruiting telomerase [68]. The CTE contains a second DAT region called 
C-DAT that when mutated doesn’t affect telomerase activity in vitro, but stops 
telomerase from maintaining telomere length in vivo [110]). Unlike the N-DAT it is less 
clear if the C-DAT plays a direct role in telomerase recruitment as it wasn’t tested if the 
in vivo telomere shortening phenotype is rescued by linking the mutants to POT1 or 
TRF2 [110]. Finally, TERT is unique among reverse transcriptases in that it has an 
insertion in fingers domain (IFD), which has residues that have also been implicated in 
TPP1 binding [111-113]. Specifically, an IFD mutant, hTERT-V791Y, showed defective 
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telomerase recruitment and was not stimulated by TPP1 (and POT1) overexpression, 
suggesting that this mutation interferes with TERT-TPP1 binding. Although the TcTERT 
structures have yielded unprecedented insight into telomerase structure and function, it 
should be noted that the T. castaneum telomerase RNA subunit has not been identified. 
Moreover the TcTERT protein lacks a TEN domain and contains a relatively 
inconspicuous IFD domain. Thus it remains possible that mammalian telomerase has 
acquired new functionalities relative to its flour beetle counterpart or that these orthologs 
perform some functions using divergent structural mechanisms. 
The most comprehensive structural information available for the telomerase 
holoenzyme and its associated proteins comes from the human and Tetrahymena 
thermophila telomerase EM structures [114-116]. The negative stain EM structures for 
the human and Tetrahymena enzymes gave the first insights into the organization of the 
full RNP. The three-dimensional structure of human telomerase shows two globular 
lobes connected by a flexible linker region suggesting telomerase may form a dimer. 
This dimer was hypothesized to be formed by the H/ACA domain of TR [114,117]. This 
quaternary structure remains controversial as some reports suggest human telomerase 
acts as a monomer while others suggest that dimeric telomerase is the functional 
enzyme [114,118-120]. Atomic models were built from the low-resolution 23 Å human 
and 25 Å Tetrahymena telomerase EM maps [116].  Recently a more detailed depiction 
evolved from the cryo-EM structures of Tetrahymena and human telomerase that were 
solved to a resolution of 4.8 Å and 10.2 Å respectively [115,121,97]. The human 
structure shows an overall bilobal shape similar to the original negative stain EM map, 
however the cryo-EM structure of human telomerase depicts that one of these lobes 
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contains the catalytic core of TERT and TR; and the other contains the H/ACA domain 
bound to the biogenesis protein core composed of one TCAB1, two dyskerin, two 
NOP10, and two GAR1 protein subunits [97]. Nevertheless a gold labeling experiment 
shows the presence of a small population of telomerase that is dimeric although the 
biochemical/biological importance of this, if any, remains unknown [97]. The model built 
from the cryo-EM map further depicts the formation of a TERT ring similar to that of 
TcTERT (Figure 1.7B). In 2015 an 8.9 Å structure of Tetrahymena telomerase was 
published [115]. This resolution allowed determination of secondary structure elements 
and the building of a structural model with the help of solved crystal and NMR structures 
of the protein subunits (or their close homologs) and the corresponding RNA. This 
structure, which confirmed the monomeric status of Tetrahymena telomerase RNP, 
allowed the first opportunity to place the TEN domain with respect to the catalytic ring 
structure of TERT. The Tetrahymena TEN domain was modeled above the CTE on the 
front (active) side of the TERT ring.  The template-DNA hybrid falls in close proximity to 
the TEN domain consistent with NMR data that suggest an interaction between the TEN 
domain of Hansenula polymorpha and DNA-RNA hybrids [100]. The authors were able 
to identify an RPA-like heterotrimeric TEB1-TEB2-TEB3 complex and also a CST-like 
complex P75-P45-P19 complex. Interestingly, the TEN domain is part of a complex 
interaction network with the TPP1 homolog p50, RPA homologs TEB1, and TEB2, and 
the IFD. The recently published 4.8 Å resolution structure of Tetrahymena telomerase 
reveals the structural details of this complex interaction network even further by 
providing the first structural information about both p50 and the IFD (Figure 1.8). The 
IFD forms an L shape that begins with two interacting helices that form the short arm of 
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the L and are connected by the long arm of the L which is made up of a long extended 
β-sheet region termed as the TRAP (Figure 1.8). The TRAP is able to interact with the 
TEN domain, RBD, and RT to form a newly discovered third ring that helps trap the 
pseudoknot of TR onto the TERT ring [121]. The IFD and TEN domain are shown in 
close proximity and form a surface on TERT that is in close proximity to p50. p50 forms 
an OB fold like that of TPP1 (Figure 1.8). It is made up of a six stranded β-barrel that 
places its TEL patch like region in close proximity to the TEN and IFD [121]. This 
structure provides the first three-dimensional insights into how telomerase may be 
recruited to the telomere in the human system and supports the previous data that 
implicates the importance of the TEN and IFD domains of human telomerase in the 
enzymes recruitment to the telomere through TPP1. 
1.5 Dyskeratosis congenita; a telomerase deficiency disease 
While expression of telomerase in somatic cells can have adverse 
consequences, telomerase expression in stem cells is imperative for continued 
replication over the course of a species lifespan [21]. Therefore it is not surprising that 
mutations in telomerase or telomerase-associated factors can lead to a variety of 
telomerase deficiency diseases called telomeropathies. The most notable 
telomeropathy is called dyskeratosis congenita (DC). DC is an inherited bone marrow 
failure syndrome that is initially identified by a diagnostic triad of nail dystrophy, oral 
leukoplakia, and skin hyperpigmentation [23,22]. Its mode of inheritance can be variable 
as it has been shown to be X-linked recessive, autosomal recessive, or autosomal 
dominant [122,123].  Patients with DC also have a predisposition to a variety of cancers, 
aplastic anemia, liver disease, and pulmonary fibrosis [122]. At a molecular level DC is 
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characterized by having blood leukocyte telomere lengths in the less than first percentile 
for the patient’s age. Patients with DC often suffer from bone marrow failure as a result 
of a depleted hematopoietic stem cell pool [123,22,14]. 
Given that the TEL patch is imperative for telomerase recruitment it can be 
predicted that mutations in the TEL patch would lead to telomeropathies, such as DC.  
Indeed a mutation in the OB domain of TPP1 was identified in two separate families, 
adding it to the list of ten other genes 
(DKC1, TERC, TERT, RTEL1, TINF2, CTC1, NOP10, NHP2, WRAP53, and PARN) that 
are mutated in patients with DC [124,125]. Our lab was involved in identifying a 
mutation in a patient that had a particularly severe form of DC called Hoyeraal-
Hreidarsson (HH) syndrome [124]. HH Patients have even shorter telomeres than most 
DC patients, making them susceptible to additional complications such as 
immunodeficiency, developmental delay, and cerebellar hypoplasia [126,123]. The 
second patient identified by a separate lab suffered from hematopoietic deficiencies and 
aplastic anemia, but not HH [125]. Using whole exome sequencing, the two 
independent research groups found that both patients were heterozygous for an in 
frame deletion of lysine 170 of TPP1. While deletion of lysine 170 was shown to affect 
telomerase recruitment and telomerase processivity, it was unclear how lysine 170, 
which is not part of the TEL patch, impacted telomerase action. While telomeropathies 
like DC can be devastating, the recent gains in our understanding of the holoenzyme 
may lead to development of individual therapies that could combat the variety of 
mutations in telomerase associated genes that lead to telomere shortening seen in 
patients. 
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1.6 Dissertation outline 
Although previous studies by our lab and others have identified individual 
patients suffering from telomeropathies with an in frame deletion of lysine 170 in TPP1 
protein, the mode of action of this mutation was unclear. Chapter 2 contains structural, 
biochemical, and genetic data that describe in detail how an in frame deletion of lysine 
170 in TPP1 affects telomerase action. Biochemical and cell biological assays were 
performed to show how deletion of lysine 170, but not its substitution to alanine, 
impaired telomerase localization and function at telomeres. Crystal structures of the OB 
domain of TPP1 harboring either the lysine deletion or a lysine to alanine substitution 
showed how the disease mutation altered the orientation of two critical glutamates in the 
TEL patch. Ultimately, CRISPR-Cas9 technology was used to introduce one copy of 
TPP1 K170Δ into HEK293T cells and demonstrate progressive telomere length 
shortening over time – recapitulating the cellular hallmark of DC and other 
telomeropathies. Chapter  2 is an adaption of a research paper published in 
Proceedings of the National Academy of Sciences of the United States of America in 
2016 [127].  
While the surfaces on TPP1 that are responsible for recruiting telomerase have 
been studied extensively, the corresponding surface on telomerase that interacts with 
TPP1 has remained largely elusive.  Biochemical, crystallographic, and EM studies 
have begun to elucidate many important details about telomerase. These studies 
provide insight into how its RNA and protein subunits work together to synthesize 
nucleotides at the extreme ends of chromosomes. Recent cryo-EM structures of both 
human and Tetrahymena telomerase have shed light on the overall organization of this 
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complex holoenzyme. The most recent 4.9 Å Tetrahymena telomerase structure gives 
the first structural information on how telomerase might be recruited to the telomere, 
building on the biochemical experiments that identified the TEN domain and IFD of 
TERT as being critical elements for this process. Still it is not known what surface on 
telomerase is involved in the interaction with the TEL patch and NOB region of TPP1. 
Chapter 3 focuses on using an alanine scanning mutagenesis screen to uncover 
regions in both the TEN domain and IFD that are important for recruitment of 
telomerase through its interaction with TPP1. Mutations that were found to affect 
telomerase recruitment were subjected to two additional tests to determine how they 
affect the ability of POT1-TPP1 to stimulate telomerase processivity and the ability of 
telomerase to maintain telomere length in vivo. Finally, Chapter 4 discusses conclusions 
and ongoing work along with future directions for the research presented in Chapters 3 





Figure 1.1 The shelterin complex facilitates end protection and end replication. 
Schematic showing the six proteins of the shelterin complex (TRF1, TRF2, RAP1, TIN2, 
TPP1, and POT1) protecting chromosome ends from ATM and ATR mediated DNA 
damage response. The schematic also depicts how the shelterin complex is able to 




Figure 1.2 Domain diagrams of TRF1, TRF2, TPP1, and POT1. 
Domain diagrams of the four shelterin proteins discussed in detail in the text. TRFH: 
TRF homology domain. OB: oligonucleotide/oligosaccharide-binding domain. PDB: 





Figure 1.3 Single stranded DNA end protection.  
(A) Left: the solved crystal structure of the TEBP-α-β in complex with ss DNA (5’-
d(GGGTTTTGGGG)-3’) (PDB ID: 2I0Q). The DBD and TEBP-β binding domain of 
TEBP-α are shown in forest green and split pea green, respectively. The TEBP-α 
binding domain and OB domain of TEBP-β are shown in blue and cyan, respectively. 
Right: The human POT1 DNA binding domain (DBD; PDB ID: 1XJV) shown in green in 
complex with telomeric DNA (5’-d(TTAGGGTTAG)-3'). The DNA is shown in cartoon 
representation. B) Views showing stacking interactions between the two OB domains of 
hPOT1 DBD and telomeric DNA. The stacking protein and DNA residues are shown in 
stick representation. C) Views of TEBP-α DBD in complex with telomeric DNA (left; from 
the TEBP-α-β-DNA structure) and POT1 DBD in complex with telomeric DNA (right) to 
highlight the different tracks adopted by the DNA molecules in the two structures. The 





Figure 1.4 Structures of TPP1 domains. 
(A) The crystal structure of the C-terminal domains of POT1 (green) in complex with the 
POT1 binding domain (PBD) of TPP1 (blue) (PDB ID: 5UN7 and 5H65). B) Left: Overlay 
of the human TPP1 OB domain (dark blue; PDB ID: 2I46) and the OB domain of TEBP-
β (cyan; PDB ID: 2I0Q). Right: Surface view of the TPP1 OB domain. TEL patch 
residues are shown in red and NOB residues are shown in orange. 
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Figure 1.5 Domain layout of Telomerase RNA and Telomerase Reverse 
Transcriptase.  
(A) Cartoon of the secondary structure of human telomerase RNA (TR). TRE: 
Telomerase Recognition Element. TBE: Telomerase Boundary Element. Secondary 
structure adapted from figures in Schmidt et al. Genes and Development 2015, and  
Nguyen et al. Nature 2018. (B) Domain diagram of human TERT shown with several 
functional elements; the position of the IFD is highlighted in the reverse transcriptase 
domain. TEN: telomerase N-terminal domain, TRBD: telomerase RNA binding domain, 
RT: reverse transcriptase domain, CTE: C-terminal extension, N-DAT: N-terminal 
dissociates activities of telomerase, VSR: vertebrate-specific recognition motif, IFD: 
insertion in the fingers domain. 
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Figure 1.6 Solved structures of telomerase domains. 
(A) Oryzias latipes TERT RNA binding domain (TRBD) bound to the CR4/5 domain of 
cognate TR (PDB ID: 4O26). (B) Atomic resolution structure of the CTE (thumb) domain 
of human TERT (PDB ID: 5UGW). Dyskeratosis congenita (DC) associated mutations 
are highlighted in red. (C) Crystal structure of Tetrahymena telomerase TEN domain 






Figure 1.7 Structure of the TERT ring from Tribolium castaneum and human 
telomerase. 
(A) The Tribolium castaneum TERT ring bound to an RNA-DNA hairpin (PDB ID: 3KYL). 
Nucleic acid is rendered in cartoon representation with the RNA in red and DNA in 
black. The TRBD domain is shown in purple, the fingers and palm are shown in yellow, 
and the thumb is shown in blue. (B) The human TERT ring bound to an RNA-DNA 
complex (PDB from supplementary information of Nguyen et al. Nature 2018). Nucleic 
acid is rendered in cartoon representation with RNA in red and DNA in black. The TRBD 
is shown in purple, the RT domain (fingers and palm) are shown in yellow, the CTE 
(thumb) is shown in dark blue, the TEN domain is shown in cyan. 
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Figure 1.8 Structure of the TEN, IFD, P50, and TEB complex of Tetrahymena 
telomerase. 
Close up view of the model of the Tetrahymena telomerase structure built from the 4.8 
Å cryo-EM map (PDB ID: 6D6V) that includes p50 (red), the TEB1-TEB2-TEB3 complex 





Chapter 2  
 





Telomerase is a unique ribonucleoprotein complex that helps solve the end 
replication problem by synthesizing telomeric repeats at the ends of linear 
chromosomes. This action is important to facilitate continued cell division in cell types 
such as germ line and stem cells. In fact mutations in telomerase and telomere 
associated genes can lead to a variety of stem cell failure diseases. The most 
prominent of these diseases is called dyskeratosis congenita (DC). Here we describe 
the structural and functional consequences that an in frame deletion of amino acid K170 
found in the OB domain of TPP1 protein has on telomere biology. 
                                            
2
 A modified version of this chapter is published in Proceedings of the National Academy of Sciences 
(DOI: 10.1073/pnas.1605685113)) I expressed and purified the proteins used for the primer extension 
assays and pull down experiments. I performed pull down experiments and carried out IF-FISH 
experiments to test for telomerase recruitment. Both Valerie Tesmer and I quantified all IF-FISH images.  
I purified protein, obtained crystals, and solved the structures of TPP1 constructs. Together Kamlesh 
Bisht and I performed the telomere ChIP experiments and the first replicate of the telomerase assay in 
Figure 2.1. I performed the telomerase assay in Figure 2.2. The WT TPP1 and the E169A/E171A stable 
cell lines were created by Jayakrishnan Nandakumar as previously described [5]. Kamlesh Bisht created 
the K170Δ and K170A stable cell lines, CRISPR cell lines, performed TRF blots, and performed the 




The discovery of the TEL patch of TPP1 prompted the prediction that this region 
could be a hotspot for mutations that cause telomerase-deficiency diseases such as 
DC. Our lab and others recently reported a case of a severe variant of DC, Hoyeraal-
Hreidarsson syndrome (HH) [124], in which the proband was heterozygous for a 
deletion of a single amino acid of the TPP1 protein, namely, lysine 170 (K170) [124]. 
This study placed TPP1 on a list with ten other genes (DKC1, TERC, TERT, RTEL1, 
TINF2, CTC1, NOP10, NHP2, WRAP53, and PARN) that are found mutated in DC and 
other telomere-related disorders [128]. Indeed, a heterozygous TPP1 K170Δ mutation 
was also reported in another unrelated family, where it was implicated in causing 
aplastic anemia and other related hematopoietic complications in the proband [125]. In 
both families, the presence of the K170Δ mutation correlated strongly with short 
telomeres. Transient overexpression of K170Δ in cultured human cells resulted in a 
decrease in telomerase recruitment [125,124] and a reduction in the ability of TPP1 to 
stimulate telomerase processivity (the ability of telomerase to continue DNA synthesis 
without dissociating from a bound primer) [124]. These results invoke a direct role for 
the K170Δ mutation in reducing telomerase function in dividing cells. However it is 
unknown whether the heterozygous K170Δ mutation is sufficient to cause telomere 
shortening in dividing human cells without additional genetic modifiers. 
The placement of K170 directly adjacent to E168, E169, and E171 strongly 
suggests that this amino acid facilitates the ability of the TEL patch to recognize 
telomerase. However, inspection of the crystal structure of the OB domain of wild-type 
(WT) TPP1 revealed that the side-chains of E168, E169, and E171, but not K170, are 
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exposed to the solvent (Figure 2.1A) [64]. This suggests that E168, E169, and E171 are 
poised to interact with telomerase, consistent with the deleterious consequences 
associated with alanine mutations of these residues [66,67,129]. In sharp contrast, the 
side-chain of K170 is buried in the TPP1-OB structure, making a cation-π interaction 
with the aromatic ring of W167 (Figure 2.1A). It is therefore unclear how deletion of this 
residue ultimately translates into reduced telomerase function. Here, we performed a 
series of biochemical, cytological, genetic, and X-ray crystallographic experiments to 
show that deletion of K170 (i) disrupts the spatial positioning of critical glutamate 
residues in the TEL patch; (ii) is sufficient to cause telomere shortening when present in 
a heterozygous context; and (iii) does not elicit dominant negative effects on the wild-
type protein. Together these studies provide valuable insights into the role of TPP1 in 
telomere length regulation, and help reveal the molecular underpinnings of telomerase 
deficiency diseases such as DC. 
2.3 Results 
2.3.1 Deletion of K170, but not its substitution to alanine, reduces telomerase 
processivity  
The deleterious effect of the TPP1 K170Δ mutation on telomerase processivity is 
not due to a defect in binding to POT1 as K170Δ binds POT1 similar to WT TPP1 
protein (Figure 2.2A). To further understand the molecular basis of telomerase 
deficiency caused by this DC mutation, we engineered a K170A mutation in the TPP1-N 
vector for expression in E. coli. [TPP1-N encodes amino acids 90-334 of human TPP1, 
a construct of TPP1 that is sufficient for binding POT1 and telomerase, and amenable to 
in vitro studies [64].] TPP1-N constructs of K170A, WT, K170Δ, and E169A/E171A (EE-
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AA) proteins were purified as described previously [64,130] (Figure 2.2B). We 
performed direct primer extension assays to determine how each of the TPP1-N 
variants contributes to telomerase processivity in the presence of POT1 (Figure 2.1B 
and C).  The WT protein displayed the expected increase in telomerase processivity 
[64], giving rise to a large fraction of longer DNA products. Both K170Δ and 
E169A/E171A failed to increase telomerase processivity to WT TPP1-N levels as 
expected from previous studies (Figure 2.1B and C) [124,66]. Strikingly, mutation of 
K170 to alanine resulted in only a modest reduction in telomerase processivity (Figure 
2.1B and C) that was not statistically significant in experiments performed in triplicate (P 
= 0.08). This result suggests that the positive charge of K170 is not critical for 
telomerase processivity. In sharp contrast, E169D/E171D (glutamate  aspartate 
mutations that retain negative charge), but not E169Q/E171Q (glutamate  glutamine 
mutations that are iso-steric and polar but lack the negative charge), was able to 
stimulate telomerase processivity (Figure 2.2C). These results are fully consistent with 
the structure of TPP1-OB WT, which indicates that the glutamates, but not K170, of the 
TEL patch loop are accessible to telomerase.   
2.3.2 Deletion of K170, but not its substitution to alanine, reduces telomerase 
recruitment to telomeres and telomere lengthening 
Given that deletion of K170 reduces telomerase processivity but substitution of 
K170 to alanine does not, we next asked how K170A impacts telomerase recruitment. 
To this end, we engineered HeLa cell lines stably expressing either FLAG-TPP1 K170A 
or FLAG-TPP1 K170Δ protein using the Flp-recombinase based single-site integration 
strategy [66]. We analyzed two clones each of FLAG-TPP1 K170A and FLAG-TPP1 
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K170Δ in parallel with FLAG-TPP1 WT and E169A/E171A clones that have been 
characterized previously  (see Figure 2.3C for FLAG immunoblots). We performed 
immunofluorescence (IF) to detect FLAG TPP1 and fluorescence in situ hybridization 
(FISH) against TR to detect telomerase localization in HeLa cells transiently 
overexpressing telomerase [66] The K170A mutation did not negatively impact 
telomerase recruitment, as telomerase was readily detectable at 90% of the FLAG-
TPP1 foci in cells stably expressing K170A (Figure  2.3A and B). In sharp contrast, 
telomerase recruitment was inefficient in K170Δ and E169A/E171A cells, which 
exhibited 34% and 7% telomerase recruitment to telomeres, respectively. These studies 
are in agreement with a previous study showing a severe (10-fold) reduction in 
recruitment of TERT to TPP1-OB E168R that was tethered to a LacO repeat array, but 
only a modest (< 2-fold) defect when K170A was used [68].  
Because the K170A mutation had only a modest effect on telomerase 
recruitment and processivity, we anticipated that overexpression of K170A will elongate 
telomeres akin to observations with overexpression of WT TPP1 [65,66,129]. In 
contrast, K170Δ overexpression would be expected to result in short telomeres, as 
observed with E169A/E171A overexpression (15). Indeed, overexpression of K170A 
resulted in elongation of telomeres (Figure 2.4A). The modest reduction in the slope of 
telomere lengthening in the two K170A clones compared to the WT clone (Figure 2.4B) 
is in agreement with similar effects seen in the telomerase processivity and recruitment 
results presented here and in previous LacO-tethering studies [68]. In sharp contrast, 
overexpression of K170Δ failed to lengthen telomeres as a function of time in culture 
(Figure 2.4A and B). The telomere shortening rate and the final telomere length of both 
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K170Δ clones were very similar to that of the E169A/E171A clone shown here and that 
of other E169A/E171A clones described previously [66]. This is the first demonstration 
of a cause-effect relationship between the K170Δ mutation and telomere shortening in 
human cells, providing the most direct evidence so far for the causative role that this 
mutation plays in telomere biology disorders. 
2.3.3 Deletion of K170 results in a major restructuring of the TEL patch 
The results presented thus far, considered with the structure of TPP1-OB WT, 
support the hypothesis that the side-chain of K170 is not involved in binding telomerase 
directly. To gain a deeper understanding of how this portion of the TEL patch 
recognizes telomerase, we crystallized TPP1-OB K170Δ and TPP1-OB K170A under 
conditions similar to those that yielded TPP1-OB WT crystals [64]. We solved the 
structure of these mutant proteins to 3.0 Å with molecular replacement using the WT 
structure as the search model (see Table 2.1 and Methods). The overall three 
dimensional structures of the two mutants are very similar to that of the WT structure 
(Figure 2.5A). The r.m.s. deviations of the Cα backbone (total of 282 Cα atoms aligned) 
for the WT vs. K170Δ, WT vs. K170A, and K170Δ vs. K170A structures were 0.3Å, 0.4 
Å, and 0.3 Å, respectively. However, and consistent with the functional data presented 
here, a unique feature present in the WT and K170A structures was conspicuously 
absent in the K170Δ structure. This feature is a bulge in the loop containing residues 
W167, E168, E169, K170, and E171 that we term the TEL patch “knuckle” (see Figure 
2.1A). This feature is absent in the K170Δ structure, as can be discerned in the overlay 
of the overall three-dimensional structures (Figure 2.5A) as well as the 2Fo – Fc 
electron density for this region (Figure 2.5B). Deletion of the entire K170 residue 
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displaces two of the critical TEL patch glutamates, E168 and E169, by 3.1 Å and 3.6 Å 
(at Cα positions), respectively, relative to their positions in the WT structure. In contrast, 
E168 and E169 residues are almost superimposable between the WT and K170A 
structures (Figure 2.5B). Although the electron density for side-chain atoms in the TEL 
patch loop is less well-defined compared to that for the main chain atoms in each of the 
three structures, it is reasonable to conclude that the large displacements of the Cα 
positions of E168 and E169 between the WT and K170Δ structures will translate to 
comparable displacements of the respective side-chain atoms (Figure 2.5C). Together, 
our results demonstrate that the main chain atoms of K170 facilitate a conformation of 
the TEL patch that presents the critical, negatively charged E168 and E169 side-chains 
for a productive electrostatic interaction with telomerase. 
2.3.4 A single K170Δ allele is sufficient to cause telomere shrinkage in cultured 
human cells 
The data presented thus far provide strong evidence and a structural rationale for 
a causal role of the TPP1 K170Δ mutation in telomerase dysfunction. However it is still 
unclear how this mutation, present in a heterozygous state in two unrelated families 
[124,125] is sufficient to cause severe telomere shortening. It is possible that other 
disease modifiers cooperate with K170Δ to cause telomere shortening in these families. 
However, our overexpression studies demonstrating that the K170Δ mutation reduces 
telomerase function (Figure 2.1 and Figure 2.2) support the alternative possibility that 
reducing the dose of a functional TEL patch to half is sufficient to cause telomere 
shortening via either haploinsufficiency or dominant negative effects of the mutation. 
Such overexpression studies are not suitable for distinguishing between 
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haploinsufficiency versus dominant negative effects, because TPP1 overexpression in 
these cells is 25-fold above endogenous levels [66]. The overexpressed mutant protein 
will completely replace endogenous WT protein at telomeres [because of competition of 
binding to TIN2, which recruits TPP1 to telomeres [53], causing the telomeres to 
resemble the homozygous state. To recapitulate the heterozygous nature of the K170Δ 
in the absence of overexpression caveats, we introduced the K170Δ mutation in HEK 
293T cells using CRISPR-Cas9 technology [131,132]. Figure 2.6A shows the general 
scheme for cleavage of the ACD gene (which codes for the TPP1 protein) by three 
guide RNAs (g1, g2 and g3). Using transient transfection of plasmids encoding Cas9 
and guide RNAs, we observed efficient cleavage of the gene coding for TPP1 with each 
of the three guide RNAs, and with a cocktail of the three guides (as inferred from the 
Surveyor nuclease assay; Figure 2.6 B; Methods). We were unable to detect the 
cleavage of the top predicted off-targets [133] of guide RNAs 2 or 3 (Figure 2.6C). 
Based on these results, we proceeded to cleave the TPP1 locus in HEK 293T cells 
using a combination of guides 2 and 3. Mutagenic single-stranded oligo-
deoxyribonucleotide donors (ssODNs) were used as the substrate for homology-
directed repair (HDR) of the cleaved locus.  
To introduce precise changes in the human ACD gene coding for human TPP1 
protein we designed two different ssODNs. The first contained the K170Δ mutation, 
while the second harbored only silent mutations in the coding region of TPP1 (Figure 
2.6A). The latter ssODN upon integration in the genome would yield cells expressing 
WT TPP1. However these cells would have been subjected to the same conditions (e.g. 
identical guide RNA mediated cleavage) experienced by K170Δ-edited cells. These 
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silently-edited WT cells, which we refer to as WT* cells, served as the control against 
which we compared K170Δ-edited cells. Each ssODN contained additional silent 
mutations to serve two purposes. The first set of silent mutations destroyed the 
protospacer/ PAM sequences to prevent cleavage of the gene coding for TPP1 by Cas9 
post-repair (Fig. 2.6A). The second set of silent mutations introduced a KpnI restriction 
site to facilitate the screening of clones (Fig. 2.6A). Evidence for editing was readily 
observed in both WT* and K170Δ transfection experiments based on the results of the 
KpnI screening assay (Figure 2.6D; Methods). The fraction of the intensities of the 
digestion products relative to that of the undigested products indicated the efficiency of 
intended mutagenesis (i.e. fraction of HEK 293T cells that were edited), which we 
determined to be ~5%. Next, we proceeded to isolate clones containing the K170Δ (or 
the WT*) mutation by diluting these transfected cells.  
We isolated clones that contained either the WT* mutation or the K170Δ 
mutation. The presence of the edited allele/s was inferred from KpnI digestion profiles 
and Sanger DNA sequencing of the TPP1 locus (Figure 2.6E; Table 2.2). Sanger DNA 
sequencing of the TPP1 locus in all isolated clones was consistent with the presence of 
three TPP1 alleles in HEK 293T cells. This was also in agreement with chromosome-
specific centromere FISH experiments showing that HEK 293T cells are triploid for 
chromosome 16, which contains the gene coding for TPP1 (Figure 2.7A). Partial but not 
total digestion by KpnI of PCR amplicons spanning the edited site suggested that the 
WT* and K170Δ clones were heterozygous for the engineered mutations (Figure 2.6E). 
DNA sequencing further revealed that in all WT* and K170Δ clones, the third TPP1 
allele underwent erroneous repair that resulted in gross insertion/deletion mutations 
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(“indels”) in the TPP1 gene (detailed sequence information in Table 2.2). Therefore the 
WT* clone was bi-allelic for WT TPP1 TEL patch function (Δ/wt*/wt*), representing more 
closely the status of the TPP1 gene in normal human cells (Table 2.2). The two clones 
containing K170Δ were also bi-allelic for TPP1, containing one K170Δ allele and one 
WT allele (Δ/K170Δ/wt), representative of the K170Δ genotype in individuals harboring 
this mutation (Table 2.2). All of the bi-allelic TPP1 clones showed a reduction in TPP1 
protein levels compared to the unedited cell line, as expected from the loss of one allele 
(Figure 2.7B).  
We performed telomere restriction fragment blots to determine the effect of the 
heterozygous K170Δ mutation on telomere length. The WT* clone maintained telomere 
length in a stable manner similar to unedited HEK 293T cells (Figure 2.7C). This result 
suggests that two copies of the TPP1 gene are sufficient for telomere length 
maintenance in HEK 293T cells; and that our genome editing strategy did not result in 
any unexpected changes in telomere length. Both clones that were heterozygous for the 
K170Δ mutation showed telomere shortening as a function of time in culture (Figure 
2.7C). This result demonstrates that a single copy of the K170Δ allele is sufficient to 
decrease telomere length in proliferating human cells. 
2.3.5 Presence of K170Δ does not alter the ability of WT TPP1 to facilitate 
telomerase function 
The ability of a single TPP1 K170Δ allele to elicit telomere shortening may be 
explained either by dominant-negative effects of the mutant protein on the WT protein or 
simply by a reduced dosage of WT TPP1 protein. The possibility of a dominant-negative 
mechanism becomes relevant in light of a study invoking TPP1 dimerization through its 
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OB domain in an Akt1-mediated phosphorylation-dependent manner [114]. Some 
studies also suggest that the human telomerase holoenzyme functions as a homodimer, 
although other studies contradict this notion [114,134,97]. To directly test for dominant-
negative effects of the TPP1 K170Δ protein, we first performed telomerase-catalyzed 
primer-extension assays involving two types of mutant-WT TPP1 protein-mixing 
experiments. In the first type of experiment, all reactions included TPP1-N WT protein at 
a constant concentration of 200 nM (and POT1 protein at a constant concentration of 
500 nM). TPP1-N K170Δ was titrated into these reaction mixtures (before addition of 
telomerase). As shown in Figure 2.8 A, addition of TPP1-N WT in the absence of K170Δ 
shows the characteristic stimulation of telomerase processivity (Figure 2.8A, compare 
lanes 1 and 2) [66,64]. Addition of TPP1-N K170Δ protein in sub- or superstoichiometric 
amounts to 200 nM TPP1-N WT failed to reduce telomerase processivity (Figure 2.8A, 
compare lanes 3–5 with lane 2). In the second experiment, we added increasing 
amounts of WT TPP1 protein to reactions containing K170Δ protein held at a constant 
concentration of 200 nM. Substoichiometric amounts of WT protein were sufficient to 
stimulate telomerase processivity in the presence of 200 nM K170Δ protein (Figure 
2.8A, compare lanes 14–16 with lane 10). These results suggest that the K170Δ protein 
does not exert any negative effects over the ability of WT TPP1 protein to stimulate 
telomerase processivity in vitro.  
 Next, we performed mutant-WT TPP1 mixing telomerase recruitment 
experiments in HeLa cells using IF-FISH. In these experiments, we transfected HeLa 
cells with a myc-tagged TPP1 WT-expressing plasmid (plus an empty vector plasmid), a 
FLAG-tagged TPP1 K170Δ-expressing plasmid (plus an empty vector plasmid), or a 
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mixture of plasmids for myc-tagged TPP1 WT and FLAG-tagged TPP1 K170Δ 
coexpression. Coexpression of TPP1 WT protein at levels comparable to that of TPP1 
K170Δ (Figure 2.8B) resulted in the efficient rescue of the telomerase recruitment defect 
(Figure 2.8C). We conclude from these experiments that TPP1 WT colocalizing with 
TPP1 K170Δ at telomeres is able to recruit telomerase to these foci. 
Next, we performed telomere ChIP experiments [60]. For this, HeLa 1.2.11 cells 
were transfected with plasmids encoding TERT, TR, and either TPP1 WT, TPP1 
K170Δ, or a mixture of plasmids to express both TPP1 constructs. Immunoprecipitations 
were performed with an anti-TERT antibody and the associated telomeric DNA signal 
was detected using Southern dot blots (Figure 2.8D). Although an ∼20% reduction in 
the amount of telomerase associated with telomeres was observed for K170Δ relative to 
WT, there was no evidence of a telomerase recruitment defect when a mixture of the 
TPP1 constructs was present in the cells. 
Finally, we performed a CRISPR-Cas9 knockout experiment to isolate HEK 293T 
clones containing only one functional copy of the gene coding for TPP1 (∆/∆/wt). 
Comparison of these cells to the K170Δ-edited cells described above (∆/K170∆/wt) 
could reveal any dominant-negative effects of K170Δ. Using the same CRISPR-Cas9 
strategy described above, we isolated a HEK 293T clone that contained only one 
unedited allele of the gene coding for TPP1 (∆/∆/wt) (Table 2.2). As expected, the TPP1 
protein level in ∆/∆/wt cells was less than in ∆/wt/wt cells or in unedited cells (wt/wt/wt) 
(Figure 2.9A). Telomere length measurements as a function of time in culture 
demonstrated that ∆/∆/wt cells exhibited robust telomere shrinkage (Figure 2.9B). 
Telomere shortening in ∆/∆/wt cells was accelerated compared with that in ∆/K170∆/wt 
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cells (Figure 2.9C), clearly ruling out any dominant-negative effect of the K170∆ 
mutation. The milder telomere shortening phenotype in ∆/K170∆/wt cells compared with 
the ∆/∆/wt cells is consistent with the modest (yet reproducible) ability of TPP1 K170∆ 
protein to stimulate telomerase processivity relative to the “no TPP1” control (Fig. 2.1B) 
Combined, our biochemical and cytological experiments failed to reveal a 
dominant-negative role of the K170Δ mutation in telomerase action. Therefore, telomere 
shrinkage in cells of individuals harboring the TPP1 K170Δ mutation is likely caused by 
reduced dosage of a functional TEL patch. 
2.4 Discussion 
Here, we solved the structure of a human protein mutant associated with DC. 
The TPP1–OB K170Δ structure clearly reveals the loss of a structural motif that we term 
the TEL patch “knuckle.” Loss of this motif rearranges the spatial positioning of 
glutamates E168 and E169 that are critical for telomerase recruitment and action at 
telomeres. Our structures provide a straightforward structural rationale for telomerase-
deficiency caused by K170Δ, and inspire the search for small molecules that can rescue 
the telomerase-binding defect of the K170Δ mutation. In addition, our structures also 
detail the precise contribution of the affected amino acid K170 to telomerase function. 
Given that K170A does not substantially alter stimulation of telomerase processivity, 
telomerase recruitment, or the conformation of the TEL patch knuckle, we conclude that 
K170 side-chain does not bind telomerase directly, but rather facilitates a productive 
TEL patch conformation for binding telomerase. The modest reduction in telomerase 
function caused by K170A observed here and in previous studies (17) is not easily 
explained by our crystal structures. We envision that the cation–π interaction between 
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the K170 side-chain and W167 (Figure 2.1A) contributes to the dynamics (or lack 
thereof) of the TEL patch knuckle in a manner that is (modestly) conducive to 
telomerase binding, but not captured by our (static) crystal structures. 
Gene therapy against DC will only be effective or justified if the disease mutation 
is sufficient to cause the underlying cellular phenotype (telomere shortening). Here, we 
used CRISPR-Cas9 technology to introduce the K170Δ mutation in HEK 293T cells. 
Our results clearly demonstrate that presence of a single allele of K170Δ is sufficient to 
reduce telomere length, ruling out the necessity of other genetic modifiers to elicit this 
effect. This is especially pertinent to the individual with Hoyeraal–Hreidarsson syndrome 
in our recent study, who inherited a TPP1 P491T variant (on a separate allele) in 
addition to the K170Δ mutation [124]. Our studies make the prediction that reversing the 
K170Δ mutation in the presence (or absence) of P491T will stall telomere shortening. 
However, our gene-editing studies are limited to one cell line. In this regard, a previous 
study by Sexton et al. [67] in human embryonic stem cells (hESCs) failed to elicit a 
telomere length phenotype when a TPP1 mutant lacking residues 166–172 was 
expressed in a heterozygous context. Regardless of the precise factors influencing the 
telomere length phenotype in these studies these context-dependent phenotypes 
highlight the challenges that lie ahead for gene therapies targeted at genetically defined 
diseases like DC. 
The heterozygous nature of the TPP1 disease mutation raises the possibility of 
potential dominant-negative effects, arising from the ability of TPP1 and telomerase to 
dimerize, driving telomerase deficiency in the proband. We performed protein-mixing 
experiments to directly test the effect of K170Δ on TPP1 WT function. Neither the 
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telomerase processivity nor the telomerase recruitment WT-mutant mixing experiments 
(IF-FISH and telomere ChIP) revealed any evidence for a dominant-negative effect for 
K170Δ. Assuming that our mixing experiments recapitulated the functionally relevant 
oligomeric status (if any) of TPP1 and telomerase in the cells, we conclude that the TEL 
patch performs its function independent of the oligomeric status of TPP1 or telomerase. 
Finally, the TPP1 ∆/∆/wt cells that we engineered showed robust telomere shortening, 
further ruling out the involvement of any dominant-negative effects of the TPP1 K170Δ 
mutation in human cells. 
In conclusion, the K170Δ mutation in TPP1 provided us a unique opportunity to 
dissect the structural, biochemical, and genetic underpinnings of a case of DC, yielding 
valuable insights into disease mechanism and encouraging therapeutic strategies to 
counter this disease. 
2.5 Materials and methods 
2.5.1 Plasmid constructs 
The following plasmids have been described previously: the pET-Smt3-TPP1-N plasmid 
[64] for expression and purification of human TPP1-N; the p3X-FLAG-TPP1-BI4 plasmid 
[130] for expression of human TPP1 (87 aa - 544 aa) in a doxycycline-induced manner 
in the HeLa-EM2-11ht cell line [135]; the p3X-FLAG-TPP1-CMV plasmid [129] for 
expression of human TPP1 (87 aa - 544 aa) in HeLa and HEK 293T cells; and the 
pTERT-cDNA6/myc-His C and phTR-Bluescript II SK(+) plasmids for transiently 
overexpressing telomerase [66]. The bicistronic expression vector pX330-U6-
Chimeric_BB-CBh-hSpCas9 for site-specific genome editing in cultured human cells 
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was a gift from Feng Zhang (Addgene plasmid # 42230) [133] and obtained upon 
signing an MTA.  
2.5.2 Site-directed mutagenesis of plasmids 
Mutations in TPP1-expression plasmids were introduced with fully complementary 
mutagenic primers (Integrated DNA Technologies) using the QuikChange® Site-
Directed Mutagenesis Kit (Agilent Technologies). The TPP1 sequences in the mutant 
plasmids were sequenced to confirm both the presence of the intended mutation and 
the absence of unwanted errors introduced during PCR amplification/cloning. 
2.5.3 Protein expression and purification 
WT and mutant constructs of Smt3-TPP1-N and Smt3-TPP1–OB fusion proteins were 
obtained upon purification from lysates of isopropyl β-d-thiogalactopyranoside-induced 
BL21(DE3) cells, as described previously [124]. Nickel-agarose chromatography was 
used as the first step of purification, followed by treatment with Ulp1 protease (material 
transfer agreement with Cornell University for pUlp1 vector) to cleave the Smt3 tag. 
Size-exclusion chromatography (Superdex 75; GE Life Sciences) was performed as the 
final step of protein purification. The His-Sumostar-hPOT1 baculoviral expression 
plasmid described previously [124] was used to express full-length POT1 in baculovirus-
infected High Five cells (Life Technologies) using vendor recommendations. Sumostar-
POT1 fusion protein was purified from insect cell lysates using nickel-agarose 
chromatography. The tag was cleaved with SUMOstar protease (Life Sensors) and the 
released POT1 protein was further purified by anion exchange (HiTrap Q HP; GE Life 
Sciences), and size-exclusion chromatography (Superdex 200; GE Life Sciences). 
GST-fusions of TPP1-N proteins were expressed from plasmids derived from the pGEX-
 46 
6P-2 vector (GE Life Sciences) in Escherichia coli and the GST-fusion proteins were 
purified from cell lysates using glutathione affinity chromatography following the 
manufacturer’s instructions (glutathione Sepharose 4B beads; GE Life Sciences). 
2.5.4 Telomerase activity assays 
Soluble cell extracts were prepared from HEK 293T cells that were transfected with 
TERT- and TR-encoding plasmids, as described previously [124]. The extract was used 
as the source of telomerase enzyme in direct telomerase primer extension assays 
based on previously published protocols [124]. Each 20-µL reaction containing 50 mM 
Tris⋅Cl (pH 8.0), 1 mM MgCl2, 1 mM spermidine, 30 mM KCl, 5 mM β-mercaptoethanol, 
1 µM of primer a5 (TTAGGGTTAGCGTTAGGG), 500 µM dATP, 500 µM dTTP, 2.92 µM 
unlabeled dGTP, 0.17 µM radiolabeled dGTP (3,000 Ci/mmol), and 3 µL of cell extract 
was incubated at 30 °C for 30 min. Next, 100 µL of buffer containing 3.6 M ammonium 
acetate and 20 µg of glycogen was used to quench each reaction, and the DNA 
products were precipitated with 70% (vol/vol) ethanol. The pellets were resuspended in 
H2O (10 µL), mixed with loading buffer containing 95% (vol/vol) formamide (10 µL), 
heated at 95 °C for 10 min, and resolved on a 10% (wt/vol) acrylamide, 7M urea, 1× 
TBE sequencing-size gel. Dried gels were imaged on a phosphorimager (Storm; GE), 
and analyzed using Imagequant TL (GE Life Sciences) software. Processivity 
calculations were performed as described previously [124]. 
2.5.5 GST pull down assays 
For the GST pulldowns, 150 µL of Glutathione Sepharose 4B beads (GE Life Sciences) 
were washed three times with 500 µL wash buffer [25 mM Tris (pH 7.0), 150 mM NaCl, 
and 2 mM BME). After the final wash step, the beads were resuspended in a 1:1 slurry 
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with wash buffer. To 30 µL of the bead slurry, 20 µg of GST-labeled WT TPP1-N, TPP1-
N K170Δ, or TPP1–OB (90–250) proteins were added, and the protein bead mixtures 
were incubated with rocking for 1.5 h at 4 °C. 20 µg of POT1 (amino acids 299–634) 
protein was then added to the beads and incubation was continued for a further 1.5 h at 
4 °C. Following incubation, the beads were washed three times with wash buffer as 
described above and boiled for 10 min in SDS-containing protein denaturation buffer. 
The denatured proteins samples were resolved on a 10% (wt/vol) SDS/PAGE gel and 
visualized with Coomassie blue stain. 
2.5.6 Structure determination of TPP1-OB K170Δ and TPP1-OB K170A 
Crystals of TPP1-OB K170Δ and TPP1-OB K170A were obtained by optimizing 
conditions that were reported to yield TPP1-OB WT crystals [64]. To obtain diffraction 
quality crystals of TPP1-OB K170Δ, 1 µl of protein was mixed with 1 µl of reservoir 
solution (3.6 M sodium formate, 100 mM Tris-Cl (pH 8.0) for TPP1-OB K170Δ; 3.7 M 
sodium formate, 100 mM Tris-Cl (pH 7.0), 2% methanol for TPP1-OB K170A) and 
incubated at 16 °C in hanging-well format. Crystals were cryoprotected and harvested 
as reported for WT protein [64]. X-ray diffraction data were obtained at the LS-CAT 
beam line 21-ID-D of the Advanced Photon Source. Data were processed using either 
HKL2000[136] (TPP1-OB K170Δ) or MOSFLM[137] (TPP1-OB K170A). To obtain a 
complete dataset with high redundancy, two separate datasets of TPP1-OB K170A 
were merged. For this, two individual data sets were processed using MOSFLM [137] 
followed by merging into a single dataset using BLEND (CCP4i suite) [138]. The data 
were scaled using SCALA (CCP4i) and intensities were converted to structure factors 
using CTRUNCATE (CCP4i). Molecular replacement solutions were found with 
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MOLREP (CCP4i) using the TPP1–OB WT (PDB ID code 2I46) structure as the search 
model. Residues 166–172 were removed in initial refinement steps to reduce model 
bias. The 2Fo – Fc density from restrained refinement was used to build in the deleted 
amino acids in Coot (CCP4i). Model building was performed using the program Coot 
[139] and the models were iteratively refined using REFMAC (CCP4i). As in the WT 
structure, density for the TEL patch loop/knuckle residues is only defined in one (subunit 
A) of the two subunits in the asymmetric unit. The PDB code for TPP1–OB K170Δ is 
5I2X and for TPP1-OB K170A is 5I2Y. The two new structures exhibited excellent 
geometry, and contained no residues in the disallowed regions of the Ramachandran 
plot (Table 2.1). Figures depicting structures were prepared in Pymol, with the exception 
of the panel containing electron density, which was prepared using Coot. 
2.5.7 Stable cell line generation using HeLa-EM2-11ht cells and p3X-FLAG-TPP1-
F3 plasmids  
HeLa-EM2-11ht cells were co-transfected in a 6-well format using Lipofectamine 2000 
(Life Technologies) with 1 µg each of the p3X-FLAG-TPP1-F3 (WT or mutant) and 1 µg 
of a Flp recombinase-expressing plasmid that also codes for puromycin resistance. The 
next morning, cells were selected for 24 h using puromycin (5 µg/ml; Sigma-Aldrich). 
Subsequently, fresh medium lacking puromycin but including ganciclovir (50 µM; Sigma-
Aldrich) was added and negative selection was conducted for 10 days. 12 individual 
clones were picked from each transfection and expanded. Positive clones were selected 
based on green fluorescence arising from their IRES-GFP locus downstream of the 
FLAG-TPP1 cDNA sequence. Two positive clones for each TPP1 mutant were 
expanded until they grew to confluency in 6 cm or 10 cm culture dishes and induced 
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with 200 ng/ml doxycycline to study the effect of TPP1 mutations in cells. Stable cell 
lines expressing TPP1 WT and TPP1 E169A/E171A used in this study were engineered 
in a similar fashion, and have been described previously [130]. 
2.5.8 CRISPR-Cas9 mediated TEL patch mutagenesis in HEK 293T cells  
The Zhang Laboratory (Broad Institute of MIT and Harvard, McGovern Institute for Brain 
Research, and Departments of Brain and Cognitive Sciences and Biological 
Engineering, Massachusetts Institute of Technology, Cambridge, MA) open access 
CRISPR design tool was used to design guide RNAs against the gene coding for TPP1 
(crispr.mit.edu/). An ∼200-bp sequence spanning exon two, which encodes the TEL 
patch of TPP1, was submitted to the CRISPR design tool for guide RNA design. Based 
on a high CRISPR design tool score and low probability off target cleavage events, a 
total three guide RNAs were selected for cloning. The selected guide-sequence 
oligonucleotides were annealed, phosphorylated using T4 polynucleotide kinase 
enzyme, and cloned into the Bbs1 site of the bicistronic expression vector pSpCas9 (BB 
# 42230) (30). The sequences of guide RNA used to cleave TPP1 were as follows: 
(Guide1- GTTCGGCTTCCGCGGGACAG; Guide2- AGAAGGAGTTCGGCTTCCGC, 
Guide3- GAGAAGGAGTTCGGCTTCCG). 
2.5.8.1 ssODN design. 
ssODNs with desired mutations were used as a template to introduce TEL patch 
mutations in the gene coding for TPP1. The ssODNs were designed to contain ∼75 
bases flanking sequences on each side of the mutation site. To avoid any cleavage 
after repair has occurred, silent mutations were introduced to destroy the spacer/PAM 
sequences in the ssODNs. Silent mutations creating a Kpn1 restriction site on the 
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mutated locus were also introduced to facilitate screening of repaired clones. The 
sequences of the designed ssODNs are as follows. Note that intronic sequences are 
shown in lowercase and exon 3 sequences are shown in uppercase. The introduced 
Kpn1 site (GGTACC) is underlined. In the K170Δ ssODN, the deletion of the K170Δ 
codon (AAG) is denoted by an asterisk (*). The italicized “AGA” sequence is a silent 
mutation (replacing the CGC codon for arginine) that destroys the PAM sequence to 









2.5.8.2 Surveyor nuclease assay to determine cleavage efficiency. 
For the Surveyor nuclease assay, 0.3 × 106 HEK 293T cells were transfected in 12-well 
plates with 1 μg of guide RNA containing plasmids using 2.5 μL Lipofectamine 2000 
(Life Technologies). Cells were ∼80% confluent at the time of transfection. After 72 h of 
transfection, cells were trypsinized and harvested by centrifugation. Genomic DNA from 
collected cells was prepared using GenElute Mammalian Genomic DNA Purification Kit 
(#G1N70; Sigma). Next, 150–200 ng of isolated genomic DNA was used for PCR 
amplification with Surveyor primer pairs using Phusion DNA polymerase in a 50 μL 
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reaction volume. After PCR, 4 μL of each reaction was loaded on an agarose gel to 
check the uniformity and efficiency of amplification among different samples. 
Amplification products were PCR purified using a PCR purification kit (#28106 Qiagen) 
and subjected to the Surveyor nuclease assay using the manufacturer’s protocol 
(Surveyor Mutation Detection Kit; catalog #706025; Transgenomic). Upon completion of 
the reaction, the products were visualized using ethidium bromide-stained, 2% (wt/vol) 
GTG agarose gels. 
2.5.8.3 Efficiency of TEL patch mutagenesis using ssODNs. 
For efficiency of TEL patch mutagenesis using ssODNs, 0.3 × 106 HEK 293T cells were 
transfected in 12 well plates with 1 μg of puromycin-resistant guide RNA containing 
plasmids and 1.2 μL (10 μM) of mutagenic ssODN, using 3.5 μL Lipofectamine 2000 
and OptiMEM medium. Twenty min later, the mixture was added drop-wise to cells that 
were incubated in antibiotic-free medium. After 5 h the media was changed to antibiotic-
containing media. One day later, 1 μg/mL puromycin was added to the media. Three 
days post-transfection, cells were trypsinized and ∼2,000 cells were added per 10-cm 
dish to allow for colony formation; the remaining cells were used to test the efficiency of 
repair using Kpn1 digestion as follows. 
To check the efficiency of desired mutagenesis, genomic DNA was prepared and the 
TPP1-TEL patch locus was PCR-amplified as already described for the Surveyor assay. 
Twenty microliters of the amplified DNA was incubated in a 30-μL reaction volume in the 
presence or absence of Kpn1 for 1 h. The reaction products were visualized using 
ethidium bromide staining of a 2% (wt/vol) GTG agarose gel. The amount of DNA 
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digested with Kpn1 was visible as smaller size DNA fragments (of predictable size), 
providing an estimation of the efficiency of mutagenesis. 
2.5.8.4 Isolation and culture of TEL patch mutant clones. 
After 14–16 d post-seeding (∼2,000 cells were seeded on a 10-cm culture dish), 
colonies were readily observable under a light microscope. Each isolated colony was 
picked with the help of pipette tip under the microscope and transferred to a 96-well 
plate (master plate) and incubated for ∼1 wk. At this time point each 96-well plate was 
trypsinized and half of the cells were transferred to a second plate (replica plate). Both 
the plates were incubated further for 4 d. Next, the replica plate was used for genomic 
DNA preparation using the ZR-96quick-gDNA kit (Zymo Research). Isolated genomic 
DNA from each well of the 96-well plate was subjected to PCR amplification and Kpn1 
restriction digestion, as described above. Based on the Kpn1 sensitivity, wells with 
positive clones were marked in a master plate and expanded for genotyping, Sanger 
DNA sequencing, and further experiments. 
2.5.8.5 Genotyping of TEL patch mutant clones. 
PCR products spanning the TPP1 mutation site obtained using the genomic DNA of the 
edited cell lines as template were cloned into vectors using the T/A cloning strategy 
(#A1360, pGEM-T Easy Vector System I, Promega). At least 12 separate bacterial 
clones were sequenced using Sanger sequencing to obtain sequence information for all 
three TPP1 alleles in these HEK 293T clones. 
For generating a TPP1 double KO (Δ/Δ/wt), we used a single KO clone (Δ/wt/wt) that 
we isolated during clonal isolation of WT* and K170Δ edited cells. The single KO cells 
were transfected with plasmids coding for guide RNAs 2 and 3, and the WT* ssODN. 
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Clones were isolated and analyzed as already described. In addition to isolating a TPP1 
double KO clone, we were also able to isolate a second WT* clone (WT* clone #2) in 
this experiment. 
2.5.9 Immunoblotting 
Immunoblotting was performed using standard protocols in combination with the 
following antibodies at the specified dilutions: mouse monoclonal anti-FLAG M2-HRP 
conjugate (Sigma; A8592; 1:20,000), mouse monoclonal anti-c-myc antibody 
(Developmental studies hybridoma bank; 1:500) mouse monoclonal anti-β-actin 
antibody (Sigma; A5441; 1:10,000), and rabbit polyclonal TPP1 antibody (Bethyl 
laboratories; A303-069A; 1:2,500). Secondary horseradish peroxidase-conjugated goat 
antibodies against rabbit IgG and against mouse IgG (Santa Cruz Biotechnology; 
1:10,000) were used to reveal the primary antibodies using chemiluminescence 
detection by ECL plus reagents (Pierce ECL Western Blotting Substrate; Thermo 
Scientific). The data were visualized and quantified using a gel-documentation system 
(ChemiDoc™ MP System; BioRad). 
2.5.10 Immunofluorescence (IF) and fluorescence in situ hybridization (FISH) 
microscopy 
IF-FISH experiments for telomerase recruitment were performed as described 
previously[130]. Briefly, IF was performed prior to FISH. Mouse monoclonal anti-FLAG 
M2 (Sigma; F1804; 1:500) in combination with Alexa Fluor 568-conjugated anti-mouse 
IgG (Life Technologies) was used to detect FLAG-tagged TPP1 proteins by IF. A 
mixture of three Cy5-conjugated TR probes[140] (30 ng of each probe per coverslip) 
was used to detect TR. For detecting myc-tagged proteins, we used the mouse 
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monoclonal anti-c-myc antibody (Developmental studies hybridoma bank; 1:250). 
Imaging was performed with a laser scanning confocal microscope (SP5; Leica, 
Germany) equipped with a 100X oil objective.  Images were processed using ImageJ as 
well as Adobe Photoshop, and colocalizations were quantified manually by separate two 
individuals.  Pseudocolored representative images are shown in figure panels. Mean 
and standard deviation of three experiments, each involving at least 100 telomeric foci, 
were plotted for each TPP1 stable cell line.   
2.5.11 Telomere length analysis 
Telomere length analysis was performed as described previously with a few 
modifications[130]. Genomic DNA was isolated from confluent 6 well plates of the 
FLAG-TPP1 expressing stable cell lines using the GenElute kit (Sigma). Genomic DNA 
(1 µg) was restriction digested with frequent cutters Hinf1 and Rsa1 overnight at 37°C. 
The DNA digests were run on a 0.8% 25 cm long Agarose-1X TAE gel at 80 V until the 
250 bp marker migrated to the bottom of the gel. The gel was imaged using a florescent 
ruler and transferred to a sheet of dry Whatman filter paper, and dried at 55°C for one h. 
After drying the filter paper was removed and the gel was incubated first in buffer 
containing 0.25 M HCl followed by incubation in buffer containing 0.5 M NaOH, and 
finally shaken in solution containing 0.5 M Tris-Cl and 1.5 M NaCl (pH 7.5) for 30 min. 
The gel was then prehybridized in Church buffer (0.5 M sodium phosphate buffer [pH 
7.2], 1% bovine serum albumin [BSA], 1 mM EDTA, 7% SDS) for 30 min at 60°C in a 
rotating hybridization oven. 5’ 32P-labeled (with T4 PNK; NEB) telomeric probe of 
sequence (TTAGGG)4 was added (20 million cpm) and hybridization continued 
overnight at 55°C. The hybridization solution was discarded and the gel was washed 
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with buffer containing 0.1X SSC. The gel was then exposed to a phosphorimager 
screen for 24-72 h, and analyzed using the Imagequant TL software. The gel was 
calibrated using the known molecular weights of the DNA ladder, and the mean 
telomere length for each lane was plotted as a function of population doubling (PD) for 
each cell line. A linear regression (MS Excel) was used to calculate the rate of telomere 
elongation. 
2.5.12 Telomere chromatin immunoprecipitation 
Ten-centimeter culture dishes containing HeLa 1.2.11 cells were transfected with 9 µg 
TR-encoding plasmid, 3 µg TERT-encoding plasmid, and either 3 µg of TPP1 WT 
plasmid, 3 µg of TPP1 K170Δ plasmid, or a mixture containing 1.5 µg each of TPP1 WT 
and TPP1 K170Δ plasmids using Lipofectamine 2000 following the vendor’s 
recommendations. Subsequent to cross-linking with formaldehyde and cell lysis, 25% of 
the lysates were kept aside as whole-cell extract samples. Immunoprecipitation was 
performed on the remaining 75% of the lysates using 4 µg of mouse anti-TRF2 
4A794.15 (Novus Biological; NB100-56506) and 5 µL rabbit monoclonal TERT (C-term) 
antibody (Epitomics; 1531-1) antibodies. Hybridization was performed in Church buffer 
[0.5 M sodium phosphate buffer (pH 7.2), 1% BSA, 1 mM EDTA, 7% (wt/vol) SDS] 
using 32P-labeled (TTAGGG)4. Following hybridization, membranes were washed to 
reduce nonspecific binding of the probe, imaged using a phosphorimager (Storm; GE 
Life Sciences) and quantified using Imagequant TL (GE Life Sciences) software. The 
TERT-associated telomeric DNA signal for each sample was normalized with the TRF2-
associated signal (obtained via immunoprecipitation using an anti-TRF2 antibody), 
which was assumed to remain constant across all samples. 
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2.6 Figures and Tables 
 
Figure 2.1 The main chain, but not the side-chain, of TPP1 K170 is important 
for stimulating telomerase processivity. 
(A) Ribbon depiction of a part of the TPP1-OB wild-type crystal structure (PDB: 2I46) 
with the TEL patch loop (amino acids: 166-171) shown in stick representation. The 
protrusion in the loop is referred to here as a “knuckle”. (B) Direct primer extension 
assays with telomerase extracts performed in the presence of purified POT1 (500 nM) 
and the indicated TPP1-N proteins (500 nM). “No TPP1” indicates a reaction lacking 
TPP1-N and POT1. The number of hexameric (GGTTAG) telomeric repeats is indicated 
on the left. (C) Quantification of telomerase processivity from triplicate experiments of 




Figure 2.2 POT1-binding and telomerase stimulation analysis of TPP1 TEL patch 
mutants.  
(A) Pull down of human POT1 (amino acids 299–634) on glutathione (GSH) beads 
containing the indicated GST–TPP1 fusions. The asterisk (*) indicates a prominent 
degradation product that copurifies with TPP1-N, which is approximately equal in size to 
GST–TPP1–OB. (B) Coomassie-stained SDS/PAGE showing uniform purity of the 
indicated TPP1-N protein constructs; EE-AA indicates E169A/E171A. (C) Primer 
extension assay with the indicated TPP1 mutants with quantification of processivity 





Figure 2.3 The main chain, but not the side-chain, of TPP1 K170 is important for 
telomerase recruitment. 
(A) FISH was used to detect TR (red) and IF was used to detect the indicated FLAG-
TPP1 proteins (green). Clonal cell lines of TPP1 K170Δ and K170A were analyzed in 
conjunction with previously characterized clones of TPP1 WT and E169A/E171A. 
Yellow spots in the “Merge” panel indicate recruitment of telomerase to telomeres. 
(Magnification: 100X) (B) Quantification of data of which D is representative. The 
average “% FLAG-TPP1 foci that contain TR” and SDs (error bars) of 10 fields of view 
(30–100 cells total) were plotted for the indicated stable cell lines. (C) Immunoblot 
showing comparable protein levels of FLAG-TPP1 in the indicated cell lines stably 




Figure 2.4 The main chain, but not the side-chain, of TPP1 K170 is important for 
maintaining telomere length. 
(A) Telomere restriction fragment (TRF) Southern blot of genomic DNA from stable cell 
lines expressing the indicated TPP1 constructs. (B) Shown on the left is the 
quantification of data shown in panel A after subtracting the telomere length at “day 0.” 
On the right is the quantification of mean TRF length from data shown in panel A.  
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Figure 2.5 Deletion of K170 restructures the loop that harbors the critical 
glutamate residues of the TEL patch of TPP1.  
(A) Ribbon diagrams of TPP1-OB K170Δ (red, Left) and TPP1–OB K170A (tan, Center) 
along with the overlay of these structures on the structure of TPP1–OB WT (WT in 
green, Right). (B) Overlay of the backbone traces for amino acids 166–171 of the three 
structures along with the 2Fo – Fc electron density for TPP1–OB K170Δ contoured at 
1.1 σ (Left); or the 2Fo – Fc electron density for TPP1–OB K170A contoured at 1.1 σ 
(Center); or without any electron density displayed (Right). Single arrowheads indicate 
the TEL patch knuckle, and the double-headed arrows indicate the displacement of 
E168 and E169 in TPP1–OB K170Δ relative to their positions in the WT structure. The 
PDB code for the previously published TPP1–OB WT structure is 2I46. (C) Stick 
representations of the TPP1–OB mutant crystal structures. Overlay of the stick 
representations of amino acids 166–171 of TPP1–OB K170Δ and TPP1–OB WT (Left); 




Figure 2.6 Introducing the TPP1 disease mutation in cells using CRISPR-Cas9 
technology. 
(A) The ACD gene coding for TPP1 protein is shown with exons as boxes and introns 
as lines. The sequence in exon #3 flanking the K170Δ codon is shown (WT) along with 
the “NGG” PAM sequences (underlined) and the cut sites (arrows) for the three guide 
RNAs (g1, g2, and g3). The mutagenic ssODN sequences to introduce WT* and K170Δ 
mutations are also shown; silent mutations to introduce the KpnI site (shown in a box) 
and to destroy Cas9 recognition are italicized and depicted in bold. (B) Results of the 
PCR-based Surveyor assay for assessing the efficiency of cleavage by Cas9 are shown 
for the indicated guide RNAs targeting the ACD gene. “all” indicates a transfection 
including all three guide RNA-encoding plasmids. The bar at the top shows the 
predicted product sizes upon Cas9-mediated cleavage, and the arrowheads alongside 
the gels indicate the uncleaved and cleaved PCR products. (C) Surveyor assay to 
analyze potential off-targeting of the three guide RNAs. The guide RNAs and the 
chromosomes that harbor the off-target are indicated. (D) PCR amplicons from genomic 
DNA templates of HEK 293T cells transiently cotransfected with plasmids encoding 
Cas9 and guide RNAs 2 and 3, and indicated ssODNs, were subjected to digestion by 
Kpn1 enzyme. The bar indicates the DNA digest sizes expected from successful 
integration of the Kpn1 site into the genome. The arrowhead indicates successful 
mutagenesis with WT* and K170Δ ssODNs. (E) KpnI-digests for clones of unedited, 
WT* (clone #1) and K170Δ (clone #1 and clone #2). The partial digestion of the PCR 




Figure 2.7 A single K170Δ allele is sufficient to cause telomere shortening in HEK 
293T cells.  
(A) Representative data for chromosome 16-specific centromere FISH in HEK 293T 
cells. The three bright spots indicate the FISH signals whereas the gray background 
indicates nuclear staining (DAPI). (Magnification: 100X) (B) Immunoblot of endogenous 
TPP1 from lysates of the indicated HEK 293T clonal cell lines (Right). The identity of the 
TPP1 band was verified by its effective knock down in HeLa cells transfected with a 
previously characterized shRNA against human TPP1 (Left). (C) TRF Southern blot of 
genomic DNA from the CRISPR-Cas9 derived clones of unedited, WT* (clone #1) and 
K170Δ (clone #1 and clone #2) at the indicated days in culture. 
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Figure 2.8 TPP1 K170Δ protein does not compromise the ability of WT TPP1 
protein to facilitate telomerase function. 
(A) Telomerase primer extension involving mutant mixing and titration performed in the 
presence of TPP1-N WT and the TPP1-N K170Δ. The filled triangles indicate 100 nM, 
200 nM and 300 nM concentrations of the indicated TPP1-N construct. “–” in lanes 1 
and 9 indicate no added POT1 or TPP1 proteins. Concentrations of DNA primer (1 µM) 
and POT1 protein (500 nM) were held constant. “Proc.” indicates processivity relative to 
TPP1-N WT (200 nM). (B) Immunoblot analysis with the indicated antibodies of cell 
lysates obtained from the indicated transfections.  (C) IF-FISH was performed on HeLa 
cells transfected with either myc-tagged TPP1 WT plasmid or FLAG-tagged TPP1 
K170Δ plasmid or a mixture of the two. IF was performed with the anti-myc and anti-
FLAG primary antibodies, and TR was detected by FISH as already described in Fig. 2. 
(Magnification: 100X) Quantification performed, as in Fig. 1, is shown on the right. (D) 
Telomere ChIP experiments using anti-TERT and anti-TRF2 antibodies. The “input” 
sample contains 25% of the whole-cell extract. Quantification of telomere ChIP 
experiments performed in duplicate with the SEM indicated with error bars is shown at 
the bottom. The “Relative telomeric DNA signal on α-TERT beads (%)” represents the 
ratio of the telomeric DNA signals of the TERT and TRF2 immunoprecipitations for each 




Figure 2.9 Telomere length analysis of single and double TPP1 knockout HEK 
293T cells. 
(A) Immunoblot to detect endogenous TPP1 protein in the indicated CRISPR-Cas9 
derived TPP1 knockout HEK 293T cell lines. (B) TRF Southern blot of genomic DNA 
from the indicated CRISPR-Cas9 derived HEK 293T clones. (C) Quantification of TRF 





Table 2.1 Table of crystallography statistics. 
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Note that both in the WT* clone #1 and in the double KO cell line, one of the indels is an 
in-frame deletion that introduces new residues in addition to deleting residues normally 
present in WT TPP1 protein. These alleles can in principle give rise to truncated TPP1 
polypeptides. However, the reduction of TPP1 protein levels observed in the 


















Mapping the TPP1-Telomerase interface 
 
3.1 Abstract 
The telomeric protein TPP1 recruits telomerase to the telomere through its N-
terminal OB domain. The surface of this domain has been extensively studied and two 
separate surfaces called the TEL patch and NOB region were identified as necessary 
for TPP1 to recruit telomerase to the telomere. While the surfaces on TPP1 that is 
involved in telomerase recruitment are well defined, the corresponding interaction 
surface on TERT has yet to be fully characterized. Both the TEN domain and IFD of 
TERT have been implicated in interacting with TPP1, with one direct interaction 
between the TEN domain of TERT and the TEL patch of TPP1 being identified. Here we 
use an alanine scanning mutagenesis screen to define two regions, one in the TEN 
domain and one in the IFD, that are necessary for telomerase recruitment to the 
telomere. We then show with an in vitro primer extension assay that mutating residues 
in these regions affect the ability of TPP1 to stimulate telomerase processivity. Finally, 
we utilize a co-FISH based assay to show that these mutations affect the ability of 
telomerase to extend telomeres in vivo. 
                                            
3
 Oana Danciu helped perform site directed mutagenesis to create several IFD mutant constructs and 
aided in performing IF-FISH assays. I carried out all other experiments shown in this chapter. 
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3.2 Introduction 
Telomerase facilitates the continued division of stem and germ line cells by 
maintaining telomere length over time. Telomerase is recruited from structures called 
Cajal bodies in the nucleus to telomeres by the shelterin component TPP1. As aberrant 
telomerase expression is a hallmark of an overwhelming majority of cancers, the 
interface between the TPP1 and telomerase is a prime target for anti-cancer 
therapeutics. TPP1 is able to recruit telomerase through two specific regions found on 
its N-terminal OB domain, called the TEL patch and the NOB region (Figure 3.1A and B) 
[60,66,69,68]. We and others have highlighted the role of the TEL patch in telomerase 
recruitment by identifying and characterizing an in frame deletion of lysine 170 in the OB 
domain of TPP1 in patients suffering from telomeropathies. Lysine 170 is found directly 
in between two critical glutamates of the TEL patch and affected the ability of 
telomerase to maintain telomeres in these patients [127,125,124]. While much has been 
discovered about this interface from the side of TPP1 it is still not known which residues 
on telomerase are responsible for interacting with TPP1. To date only one direct 
interaction has been demonstrated by charge swap experiments between K78 of the 
TEN domain of TERT and E215 of the TEL patch of TPP1 [70]. Here we use an alanine 
mutagenesis screen to identify two stretches of amino acids: one in the TEN domain 
and another in the insertion in the fingers domain (IFD) of TERT that are important for 
telomerase recruitment to the telomere.  The mutagenesis screen utilized an 
immunofluorescence-fluorescence in situ hybridization (IF-FISH) assay to determine 
which mutations affected recruitment of telomerase to the telomere without abolishing 
telomerase RNP assembly. Hits from the screen were further validated in vitro with a 
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direct primer extension assay for telomerase processivity stimulation by POT1-TPP1, 
and in vivo with a co-FISH assay used to detect newly synthesized telomeres in HeLa 
cells. 
3.3 Results 
3.3.1 Design of a mutagenesis screen to identify the TERT surface that binds 
TPP1 
 Previous work has established that the TEN and IFD domains of TERT are 
important for telomerase recruitment to the telomere through the TEL patch and NOB 
regions of the shelterin component TPP1. The primary structural insights into this 
process came from the Tetrahymena telomerase cryo-EM structures (Figure 3.2A). 
These structures were the first to reveal the proximity of TEN and IFD to each other and 
to the p50 subunit (the Tetrahymena homolog of TPP1). To begin to understand what 
role these domains play in telomerase recruitment we first attempted to express protein 
constructs for the TEN domain and IFD in human cells. Interestingly, a construct that 
linked the TEN domain with the IFD using a 20 amino acid serine/glycine linker 
expressed at a much higher level than either the TEN domain or IFD construct alone 
(Figure 3.1C). This result agrees with the recently published 4.8 Å resolution structure of 
Tetrahymena telomerase. In it the TEN domain and IFD interact through a surface 
described as a three-stranded β-sheet named the IFD TRAP (Figure 3.2A). From these 
observations, we hypothesized that the TEN and IFD come together to form structural 
platform that interacts with the TEL patch and NOB region of TPP1. To map the regions 
in TERT that are critical for telomerase recruitment by TPP1 we engineered an alanine 
scanning mutagenesis screen limited to only the TEN and IFD regions of human TERT. 
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We used the crystal structure of the Tetrahymena TEN domain, the cryo-EM structure of 
Tetrahymena telomerase, and sequence alignments between human and Tetrahymena 
telomerase (Figure 3.2B and C) to generate a homology model of the human TERT 
TEN and IFD regions. We selected residues to mutate that were well conserved and 
predicted to be on the surface of the TEN and IFD regions. The screen was composed 
of eighteen mutations in the TEN domain (3 double mutants, 15 single mutants) and 
twelve mutations in the IFD (9 double mutants, 3 single mutants) (Figure 3.2B and C 
and Figure 3.3). We also utilized the previously identified K78E mutation in the TEN 
domain as a positive control for defective interaction with TPP1 [70].  
3.3.2 Scanning alanine mutagenesis reveals residues on TEN and IFD that are 
important for telomerase recruitment to the telomere 
To identify residues on telomerase that interact with TPP1 we transiently 
transfected WT or mutant TERT along with TR into a HeLa-EM2-11ht derived cell line 
that stably expresses FLAG-TPP1. We then performed immunofluorescence (IF) and 
fluorescence in situ hybridization (FISH) to determine how mutations in TERT affected 
the ability of hTR (telomerase) to colocalize with FLAG-TPP1 (telomeres). In agreement 
with previous data, we found that WT TERT was effectively recruited to telomeres, with 
97% of TR foci colocalized with FLAG-TPP1 foci, while TERT K78E showed only 46% 
of TR foci colocalized with FLAG-TPP1 foci (Figure 3.4). Eighteen TERT constructs 
from our mutagenesis screen with mutations in the TEN domain (A46I/F47Y, R48A, 
Q73A/S75A, E79A, R83A, Q86A/R87A, F115A, V119A, R120A, L141A and V162A) and 
IFD (Q722A/R72A, L725A/E727A, V747A, K757A/F759A, Q781A, R787A, and 
F809A/R811A) had 80-96% of their TR foci colocalize with FLAG-TPP1, suggesting 
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these mutations do not affect telomerase recruitment to the telomere (Figure 3.5 and 
3.7). In sharp contrast, five TERT constructs with mutations in the TEN domain (N125A, 
T128I, L139A, L140A, and R143A) had only 2%-10% of their TR foci colocalize with 
FLAG-TPP1 foci (Figure 3.4A and B). Using the model developed from the 
Tetrahymena telomerase cryo-EM structures and protein sequence alignment of the 
Tetrahymena and human proteins, N125 and T128 can be mapped to an α-helix (α5) of 
the TEN domain which is in close proximity to p50 suggesting that these residues may 
interact with TPP1 (Figure 3.3). Residues L139, L140, and R143 all map to α6 which is 
in the core of the TEN domain suggesting that these residues may play a structural role 
instead of, or in addition to, interacting with TPP1. Additionally, six mutants in the IFD 
(V790A/I792A, E793A/Q794A, S802A/S803A, L805A/F806A, and V818A/R819A) had 
only 5%-22% of TR foci colocalize with FLAG-TPP1 foci (Figure 3.6A and B). Based on 
the same Tetrahymena telomerase cryo-EM structure, residues V790 and I792 are 
found at the interface between β3 of the IFD and TEN (Figure 3.3). Residues E793 and 
Q794 are found at the interface of IFD, TEN and p50 suggesting that at least one of 
these two residues may interact with TPP1. Residues S802, S803, L805, and F806 are 
all found in the C-terminal α-helix of the IFD that along with the N-terminal α-helix of IFD 
forms the short arm of the L-shaped structure (Figure 3.3). It is possible that the short 
arm interacts with TPP1 as it is in close proximity to the N-terminus of p50 in the 
Tetrahymena telomerase structure. Our primary screen of TEN and IFD mutants 
revealed that eleven mutants were significantly defective in telomerase recruitment to 
the telomere, and mapping their location on the Tetrahymena structure suggests that 
several of these residues could be involved in a direct interaction with TPP1.  As a 
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corollary, most of the mutations that did not affect telomerase recruitment to telomeres 
are predicted to be located farther away from the telomerase-TPP1 interface based on 
our homology model of human telomerase (Figure 3.3; yellow residues).   
3.3.3 Telomerase recruitment defects of many TEN and IFD mutants occur 
downstream of telomerase assembly 
Previous experiments with TPP1 TEL patch mutants defective in telomerase 
recruitment have demonstrated that telomerase remains in Cajal bodies when not 
recruited to the telomere [124,66]. Indeed, all mutants in both the TEN domain and IFD 
that are defective in telomerase recruitment to the telomere show large TR foci, 
indicative of telomerase residing in the Cajal body. While this suggests defective 
telomerase recruitment by TPP1, it is also possible that some of these mutations disrupt 
the TERT structure in a way that would adversely affect expression. We were able to 
check TERT expression by immunoblot and found TERT constructs harboring mutations 
in the TEN or IFD were expressed (Figure 3.5C). It is also possible these mutations 
affect the ability of TERT to assemble with TR. As it is known that transfecting TR alone 
leads to large TR foci in Cajal bodies (Figure 3.8), it is possible that Cajal body 
localization of TR in the telomerase recruitment assay is a result of failed assembly of 
TR with TERT rather than due to failed recruitment to telomeres. To determine if the 
disruptive mutations identified in the recruitment assay grossly affected the ability of 
TERT and TR to assemble, a second set of IF-FISH experiments was performed.  In 
these experiments HeLa-EM2-11ht cells were transiently transfected with either wild 
type or mutant FLAG-TERT along with TR. TR foci were visualized with FISH and 
immunofluorescence was used to detect FLAG-TERT. The extent to which TR 
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colocalized with FLAG-TERT was used to confirm correct telomerase assembly. When 
the HeLa cells were transfected with WT TERT or TERT K78E 91% and 84% of TR foci 
colocalized with FLAG-TERT foci respectively (Figure 3.8). In sharp contrast to the 
drastic reduction in telomerase recruitment to telomeres, most of these mutants 
(N125A, T128I, L139, L140A, V790A/I792A, E793A/Q794A, S802A/S803A, 
L805A/F806A) showed substantial TERT-TR colocalization in Cajal bodies (quantitation 
showed ~50% or higher level of assembly), suggesting that the telomerase recruitment 
defects could not be attributed to faulty RNP assembly (Figure 3.8 and Figure 3.9). It 
should be noted that the FLAG-TERT V790A/I792A used in the assembly assay, but not 
the untagged TERT V790A/I792A construct used in telomerase recruitment assays, has 
been fully sequenced and found to have DNA mutation encoding L55M in the TEN 
domain. Although, this unintended mutation does not appear to have a negative effect 
on RNP assembly we are working to perform these assays with the correct TERT 
V790A/I792A construct. While many TERT mutations did not affect assembly, two 
exceptions were V818A/R819A (36% TERT-TR colocalization) and R143E (no TERT 
signal), which showed large reductions in both telomerase recruitment to telomeres and 
telomerase assembly (Figure 3.8 and Figure 3.9). It is therefore possible that for these 
two mutants, the observed telomerase recruitment defect is primarily derived from the 
inability of TERT to assemble with TR, although an additional TPP1-binding role for the 
mutated residues cannot be ruled out. Taking both the recruitment and assembly data 
together we have been able to identify four mutants each in the TEN and IFD that are 
greatly defective in telomerase recruitment to telomeres per se (TEN: N125A, T128I, 
L139A, L140, IFD: V790A/I792A, E793A/Q794A, S802A/S803A, and L805A/F806A). 
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3.3.4 Mutations in TEN and IFD that disrupt telomerase recruitment also affect the 
stimulation of repeat addition processivity 
It has been well established that POT1-TPP1 act to stimulate telomerase repeat 
addition processivity [64]. Two specific regions on the OB domain of TPP1 called the 
TEL patch and the NOB region have been shown to be responsible for both recruiting 
telomerase and stimulating its processivity [69,66]. To better understand if the 
telomerase residues identified here are responsible for interacting with the TEL patch 
and NOB regions of TPP1 we utilized a direct primer extension assay taking note of the 
caveat that any mutations that disrupt telomerase assembly and/or catalytic activity will 
obviate our ability to assess stimulation by POT1-TPP1. This assay has been used 
previously to show that K78 of TERT and E215 in the TEL patch of TPP1 interact using 
a charge swap [70]. Two other studies have utilized this assay to illustrate the 
importance of the interaction between TPP1 and the IFD [112,113].  As expected, 
POT1-TPP1 stimulated telomerase consisting of WT TERT by ~three fold over reactions 
without POT1 or TPP1 supplementation (Figure 3.10A and B). When we performed 
reactions that contained TERT that harbored an N125A, T128I, L139A or E793A/Q794A 
mutations, POT1-TPP1 was not able to stimulate their processivity. This, along with the 
recruitment data, suggests that these TERT residues are essential for a TPP1 
interaction. When we tested the L805A/F806A mutants we found that POT1-TPP1 was 
able to stimulate processivity ~2 fold, suggesting that the residues may play a less 
critical role in binding TPP1 (Figure 3.10A and B).  The S802A/S803A TERT mutant 
failed to show any activity in primer extension assays.This prevented analysis of this 
mutant with POT1-TPP1 (Figure 3.10A and B). More surprising however, TERT 
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harboring either an L140A or the V790A/I792A mutations also displayed no activity in 
our primer extension assays despite proper telomerase assembly (Figure 3.10A and B). 
Based on the crystal structures of the TEN domain from Hansenula polymorpha and 
Tetrahymena L140 is predicted to  contribute to the core of the TEN domain, so 
mutating it to alanine might alter the structure of the TEN domain in addition to 
disrupting a potential interaction with TPP1 [99,100]. A residue in Tetrahymena TEN 
domain corresponding to human V791 (previously implicated in TPP1 binding) was 
mapped to the TEN-IFD interface in the recent cryo-EM structure of Tetrahymena 
telomerase. Thus the V790A/I792A mutation may result in a loss of activity because 
these residues are important for the integrity of the TEN-IFD interface and therefore 
holoenzyme stability (Figure 3.3) [113,121]. Based on the same structure N125, T128, 
E793, and Q794 of human TERT are all expected to interact with TPP1 (Figure 3.3).  
3.3.5 TEN and IFD mutations compromised in telomerase recruitment are unable 
to extend telomeres in vivo 
To assess the effects of TERT mutations on telomere elongation in living cells, 
we transiently transfected the FLAG-TPP1 HeLa stable cell line with wild type or mutant 
TERT and a telomerase RNA (TR) mutant that contains a non-telomeric sequence in its 
template (3’-GCCAAC-5’). This allows us to visualize newly added mutant telomere 
repeats by performing FISH with a Cy3 labeled DNA probe that cannot hybridize to the 
canonical GGTTAG repeat, but rather binds the newly added mutant 5’-GTTGCG-3’ 
repeat. We simultaneously determined the localization of FLAG-TPP1 (telomeres) by IF, 
and the localization of the mutant TR (telomerase) by FISH. We found that the Cy3 
labeled DNA probe not only hybridizes to the newly synthesized telomeric repeats, but 
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also non-specifically to RNA found in the nucleolus (Large red spots, Figure 3.11). The 
protocol this experiment was adapted from called for the use of an RNase, but as our 
experiment relied on visualizing TR foci to determine which cells were transfected with 
telomerase, we omitted RNase treatment. As the nucleolar staining is spatially 
separated from telomeric foci, it did not interfere with our analysis.  
With transfections containing WT TERT and mutant TR, approximately 75% of 
HeLa cells that contained telomerase also contained newly synthesized mutant 
telomeres. However when TERT K78E was transfected we found that 28% of cells 
contained both TR and mutant telomeric repeats. Based on the defects in recruitment 
and the inability of POT1-TPP1 to stimulate telomerase repeat addition processivity, it is 
not surprising that transfections with TERT containing TEN domain or IFD mutations 
had significantly less cells that contained mutant telomeres than transfections with WT 
TERT (Figure 3.11 and Figure 3.12). When TERT containing N125A, T128I, or L139A 
were transfected into cells we found that between 13% and 15% of cells contained both 
TR foci and foci corresponding to newly synthesized telomeres, while L140A, 
V790A/I792A, E793A/Q794A, S802A,S805A, and L805A/F806A all displayed between 
6% and 9% of cells containing both TR foci and newly synthesized telomeres (Figure 
3.11 and Figure 3.12). These data confirm that mutations in telomerase that adversely 
impact telomerase recruitment by TPP1 also fail to extend telomeres in vivo.  
3.4 Discussion 
          Telomerase is a unique ribonucleoprotein that is able to both provide the template 
for and catalyze the synthesis of telomeric repeats at the extreme ends of linear 
chromosomes. This action facilitates continued division of stem cells by counteracting 
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the erosion of telomeres that would occur due to the end replication problem. The 
telomerase RNP is assembled from TERT, TR and other associated factors in the 
nucleus and trafficked to Cajal bodies in preparation for telomerase recruitment. 
Telomerase is then recruited to telomeres by TPP1 to facilitate chromosome end 
replication. Here I show that mutating residues in both the TEN and the IFD can result in 
a defect in telomerase recruitment, a loss of POT1-TPP1 facilitated repeat addition 
processivity in vitro, and an inability to extend telomeres in vivo.  This allows us to 
define two separate stretches of amino acids, one in the TEN domain and one in the 
IFD that are necessary for telomerase recruitment to the telomere (Figure 3.13). 
Here we set out to define regions of TERT, specifically in the TEN domain and 
IFD, that are important for telomerase recruitment to the telomere through the 
established interaction with TPP1. We were able to use an alanine scanning 
mutagenesis screen in conjunction with a series of IF-FISH experiments to define two 
stretches of amino acids, one in the TEN domain and one in the IFD, that when mutated 
affect telomerase recruitment to the telomere. We were further able to show that many 
of these mutations didn’t affect the ability of TERT and TR to assemble, confirming that 
the telomerase recruitment defect was not a consequence of compromised RNP 
assembly. Additionally, using a direct primer extension assay we were able to show that 
the repeat addition processivity of telomerase harboring telomere recruitment-defective 
mutations (N125A, T128I, L139A and E793A/Q794A) was not able to be stimulated by 
POT1-TPP1 further suggesting that the mutated residues directly interact with TPP1. 
Ultimately we were also able to demonstrate that mutations in the TEN and IFD affected 
the ability of telomerase to extend telomeres in vivo. 
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Creating a homology model of human telomerase based off of the Tetrahymena 
telomerase cryo-EM structure allows us to map the mutations that we found in the TEN 
and IFD to their predicted location in TERT and relative to the OB domain of TPP1 
(Figure 3.13). In the TEN domain this region starts with a predicted α-helix, which 
begins with N125 and contains T128. This region continues with a short flexible linker 
that contains R132 and continues into another predicted helix that contains L139, L140, 
and R143. In the IFD we identified a region that begins with a long loop/β-strand (shown 
to be a β-sheet in the Tetrahymena cryo-EM structure). This loop is in close proximity to 
the TEN domain and a portion of the loop forms part of the IFD-TRAP defined by Jiang 
et al. Cell 2018. The region of the IFD that we found to be important for telomerase 
recruitment continues into a predicted C-terminal α-helix (Figure 3.13). Together the 
stretches of residues in the TEN domain and the IFD are predicted to form a contiguous 
surface that is oriented toward TPP1 in our model. The crystal structure of the OB 
domain of TPP1 was placed in our homology model using the orientation of p50 in the 
cryo-EM structure along with the K78-E215 interaction as a guide. The NOB region of 
TPP1 is predicted to be in close proximity to the IFD residues and the TEL patch is in 
close proximity to the two predicted α-helices we found to be important for telomerase 
recruitment. While these predictions may provide a reasonable approximation of how 
TPP1 and TERT interact, a crystal structure or a high resolution cryo-EM map of the two 
proteins in complex is still required to fully define the interface between the two proteins. 
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3.5 Materials and methods 
3.5.1 Molecular cloning and site-directed mutagenesis 
All mutations in TERT were introduced into p3X-FLAG-TERT-cDNA6/myc-HisC 
and pTERT-cDNA6/myc-HisC using the QuikChange® Site-Directed Mutagenesis Kit 
(Agilent Technologies) and complementary mutagenic primers (Integrated DNA 
Technologies). The resulting plasmids were sequenced to confirm both the presence of 
the intended mutation and the absence of unwanted errors introduced during PCR 
amplification/cloning.  
3.5.2 Cell culture 
HeLa-EM2-11ht cells were used in all IF-FISH experiments. HEK 293T cells were 
used to create super telomerase extracts following previously published protocols 
[127,66]. Cells were grown at 37°C in the presence of 5% CO2 and grown in media 
containing modified DMEM (Gibco; Dulbecco’s Modified Eagle Medium; 11995-065), 
100 U/mL penicillin, 100 µg/mL streptomycin, and 10% FBS. For experiments where 
induction was necessary, doxycycline was added to a final concentration of 200 ng/mL 
to drive a tetracycline-inducible promoter within the p6X-FLAG-BI4 plasmids (FLAG-
TPP1). 
3.5.3 Immunoblots 
Immunoblotting was performed using previously published protocols with the 
following antibodies: mouse monoclonal anti-FLAG M2-HRP conjugate (Sigma; A8592; 
1:10,000), mouse monoclonal anti-FLAG M2 (Sigma; F3165; 1:10,000) . Secondary 
horseradish peroxidase-conjugated goat antibodies against mouse IgG (Santa Cruz 
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Biotechnology; 1:10,000) were used to observe primary antibodies using 
chemiluminescence detection by ECL plus reagents (Pierce ECL Western Blotting 
Substrate; Thermo Scientific). The data were visualized using a gel-documentation 
system (ChemiDoc MP System; Bio-Rad). 
3.5.4 IF-FISH to monitor telomerase recruitment to telomeres and telomerase 
assembly  
IF-FISH experiments for telomerase recruitment were performed exactly as 
described previously [127]. For telomerase assembly ~1.2 million HeLa-EM2-11ht cells 
in 6-well plates were transiently transfected using Lipofectamine 2000 (Fisher; 
11668019)  with  1 µg of  p3X-FLAG-TERT-cDNA6/myc-HisC and 3 µg of phTRmut-
Bluescript II SK (+) plasmids using the manufacturer recommended protocol. 24 h post 
transfection cells were fixed with 4% formaldehyde in PBS for 10 min at room 
temperature, washed with PBS three times. The cells were permeabilized with PBS 
containing 0.3% Triton X-100 for 5 min and subsequently blocked in PBS containing 
0.1% Triton X-100, and 3% BSA for 30 min. Cells were incubated with mouse 
monoclonal anti-FLAG M2 (Sigma; F1804; 1:500) in PBS containing 0.1% Triton X-100, 
and 3% BSA for 1 h. The cells were then washed three times in PBS for 5 min each 
wash, and incubated with Alexa Fluor 568-conjugated anti-mouse IgG (Life 
Technologies). The cells were then washed three times in PBS and fixed with 4% 
formaldehyde in PBS for 10 min at RT. After washing the cells three times with PBS the 
cells were consecutively dehydrated for 5 min each with 70%, 95%, and 100% ethanol. 
Cells were air dried for 3 min and then rehydrated with 2X SSC 50% formamide for 5 
min prior to pre-hybridizing for 1 h with hybridization buffer containing 100 mg/ml 
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dextran sulfate, 0.125 mg/ml yeast tRNA, 1 mg/ml BSA, 0.5 mg/ml salmon sperm DNA, 
1 mM vanadyl ribonucleoside complexes (VRC), and 50% formamide in 2X SSC. After 
pre-hybridization cells were transferred to hybridization solution containing a mixture of 
three Cy5-conjugated probes against TR and then incubated at 37°C for ~16 h. After 
incubation cells were washed with 2X SSC 50% formamide for 30 min each wash and 
mounted on microscope slides using ProLong Gold mounting medium with DAPI (Life 
Technologies). Imaging was performed using a laser scanning confocal microscope 
(SP5; Leica, Germany) equipped with a 100X oil objective. ImageJ and Adobe 
Photoshop were used to process all images.  
3.5.5 Protein expression and purification 
TPP1-N and POT1 proteins were prepared as described previously [127]. Briefly, 
lysates from isopropyl β-d-thiogalactopyranoside-induced BL21(DE3) cells were passed 
through a nickel-agarose (Ni-NTA) column. Following elution the proteins were treated 
with Ulp1 protease (material transfer agreement with Cornell University for pUlp1 
vector) to cleave the Smt3 tag. The final step of purification was Size-exclusion 
chromatography (Superdex 75; GE Life Sciences). The baculoviral expression plasmid 
for His-Sumostar-hPOT1 was described previously [127]. This plasmid was used to 
express POT1(1-634) in High Five cells (Life Technologies) that were infected with a 
baculovirus using vendor recommendations. Insect cell lysates were passed over a 
nickel-agarose column. After elution the sumostar tag on full length POT1 was cleaved 
with SUMOstar protease (Life Sensors) and the POT1 protein was first purified by anion 
exchange (HiTrap Q HP; GE Life Sciences), and subsequently size-exclusion 
chromatography (Superdex 200; GE Life Sciences). 
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3.5.6 Preparation of telomerase extracts 
Telomerase extracts were prepared as published previously [66].  First HEK 
293T cells were seeded into a 6 cm dish at a density of approximately 800,000 cells and 
transfected about 42 h later using Lipofectamine 2000 (Invitrogen) using the 
manufacturer’s recommended protocol. 1 μg of each p3X-FLAG-TERT-cDNA6/myc-
HisC construct, and 3 μg phTR-Bluescript II SK(+)18 were added for each transfection. 
After 24 h cells were trypsinized and plated in a 10 cm dish, and 48 h after transfection 
the cells were trypsinized and consecutively washed with DMEM containing 10% FBS 
and PBS. The detached cells were spun down at 800 rpm after each wash step. Cells 
were then resuspended in 300 µl CHAPS buffer (10 mM Tris-HCl (pH 7.5), 1 mM 
MgCl2, 1 mM EGTA, 0.5% CHAPS, 10% glycerol, 5 mM BME, 1X complete, Mini, 
EDTA-free Protease Inhibitor Cocktail (Rouche, 11836170001) and 2.5 ul 20 U/ul 
SupernaseIn (Ambion, AM2694). Resuspended cells were nutated for 20 min at 4°C, 
and following nutation, centrifuged at 14,000 x g for 10 min at 4°C. The supernatant was 
flash frozen as 30 µl aliquots in liquid nitrogen before being stored at -80°C. 
3.5.7 Direct telomerase activity assays  
Telomerase assays were performed as described previously [66,127]. Super 
telomerase extracts from HEK 293T cells were prepared as described above. Before 
starting telomerase reactions immunoblots were performed using a FLAG antibody of 
WT and mutant extracts to ensure equal amounts of telomerase were added to each 
reaction. In each reaction, the total amount of HEK 293T cell extract was 6 µl. Each 
reaction contained 500 nM POT1 and 500 nM TPP1-N (87-334) as well as 50 mM Tris–
Cl (pH 8.0), 1 mM MgCl2, 1 mM spermidine, 30 mM KCl, 5 mM β-mercaptoethanol, 1 
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µM of primer a5 (TTAGGGTTAGCGTTAGGG), 500 µM dATP, 500 µM dTTP, 2.92 µM 
unlabeled dGTP, and 0.17 µM radiolabeled dGTP (3000 Ci/mmol). Reactions 
proceeded for 1 hour at 30°C. 100 µl of buffer containing 3.6 M ammonium acetate and 
20 µg of glycogen was used to quench each reaction, and the DNA products were 
precipitated with 70% ethanol at -80°C overnight.  The pellets were resuspended in 7 µl 
H2O, then mixed with 7 µl loading buffer containing 95% formamide, and heated at 95°C 
for 5 min.  Samples were resolved on a 10% acrylamide, 7 M urea, 1X TBE sequencing-
size gel, which was then dried and imaged on a phosphorimager (Storm; GE).  All 
assays were analyzed using Imagequant TL (GE Life Sciences) software.  Processivity 
calculations were performed as previously described [127]. 
3.5.8 Detection of in vivo telomere synthesis using mutant TR IF-coFISH 
To monitor the synthesis of mutant telomeric DNA in HeLa-EM2-11ht derived 
FLAG-TPP1 stable cell lines, cells were induced with 200 ng/µl doxycycline for 48 h 
prior to transfection with TERT and TR. After 48 h induction, 1 µg of  p3X-FLAG-TERT-
cDNA6/myc-HisC and 3 µg of template mutated phTRmut-Bluescript II SK (+) plasmids 
were transfected into 6-well plates with approximately 1.2 million cells with 
Lipofectamine LTX (Fisher; 15338100) using the manufacturer recommended protocol. 
24 h post transfection cells were fixed with 4% formaldehyde in PBS for 10 min at room 
temperature and washed three times with PBS. The cells were fixed 24 h post 
transfection to both allow enough time for telomere elongation, but not allow for cell 
death presumed to be caused from end deprotection by the addition of a non-canonical 
telomeric sequence. The cells were permeabilized with PBS containing 0.3% Triton X-
100 for 5 min and subsequently blocked in PBS containing 0.1% Triton X-100, and 3% 
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BSA for 30 min. Cells were incubated with mouse monoclonal anti-FLAG M2 (Sigma; 
F1804; 1:500) in PBS containing 0.1% Triton X-100, and 3% BSA for 1 h. The cells 
were then washed three times in PBS for 5 min each wash, and incubated with Alexa 
Fluor 568-conjugated anti-mouse IgG (Life Technologies). The cells were then washed 
three times in PBS and fixed with 4% formaldehyde for 10 min at RT. After washing the 
cells three times with PBS the cells were consecutively dehydrated for 5 min each with 
70%, 95%, and 100% ethanol. Cells were then rehydrated with 2X SSC 50% formamide 
for 5 min prior to pre-hybridizing for 1 h with a hybridization buffer containing 100 mg/ml 
dextran sulfate, 0.125 mg/ml yeast tRNA, 1 mg/ml BSA, 0.5 mg/ml salmon sperm DNA, 
1 mM vanadyl ribonucleoside complexes (VRC), and 50% formamide in 2X SSC. After 
pre-hybridization cells were transferred to hybridization solution containing a mixture of 
three Cy5-conjugated probes against TR and a Cy3-conjugated PNA-(CCGCAA)3 
probe. The cells were heated at 80°C for 5 min for denaturation then incubated at 37°C 
for ~18 h. After incubation cells were washed with 2X SSC 50% formamide for 30 min 
and mounted on microscope slides using ProLong Gold mounting medium with DAPI 
(Life Technologies). Imaging was performed using a laser scanning confocal 
microscope (SP5; Leica, Germany) equipped with a 100X oil objective. ImageJ and 





Figure 3.1 Domains involved in the telomerase-TPP1 interaction. 
(A) Domain diagrams of TPP1 and TERT. TEN: telomerase N-terminal domain, TRBD: 
telomerase RNA binding domain, RT: reverse transcriptase domain, CTE: C-terminal 
extension, N-DAT: N-terminal dissociates activities of telomerase, VSR: vertebrate-
specific recognition motif, IFD: insertion in the fingers domain. (B) The solved crystal 
structure of the OB domain of TPP1 (PDB: 2I46) with TEL patch residues in red, NOB 
residues in orange, and K170 in yellow. (C) FLAG immunoblot depicting the expression 
levels of FLAG-TEN, FLAG-IFD, and the fusion construct FLAG-TEN-(SG)20-IFD. 




Figure 3.2 Structural model-based mutagenesis screen of TEN and IFD. 
(A) CryoEM model of Tetrahymena telomerase (PDB ID: 6D6V) (B) Sequence 
alignment of the TEN domain from indicated eukaryotic TERT homologs. Sequence 
alignments were performed with ClustalW and refined manually. The alignment in 
Schmidt et al. eLife 2016 was used as a guide. (C) Sequence alignment of the IFD 
sequences from indicated eukaryotic TERT homologs. Initial alignment was performed 
by MUSCLE and refined manually. In B and C, mutated residues are shown in red; 
double mutants are denoted with brackets. 
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Figure 3.3 A model of human TEN and IFD with the TPP1 OB Domain. 
Two views of a model of human telomerase generated with SWISS-MODEL using the 
Tetrahymena telomerase structure (PDB ID: 6D6V) along with the sequence alignments 
in Figure 3.2B and C. In green is the TPP1 OB domain (PDB ID: 2146). TEL patch 
residues are in red and NOB residues in orange. The TEN domain (cyan) and IFD 
(violet) are both homology models. Residues in yellow are mutated residues in hTERT 
that had no effect on telomerase recruitment. Residues in red (TEN) or pink (IFD) are 




Figure 3.4 Several mutations in the TEN domain affect recruitment of telomerase 
to telomeres.  
(A) Stable HeLa-EM2-11ht clones overexpressing FLAG-TPP1 and transiently 
transfected with TR and the indicated TERT mutant were analyzed for telomerase 
recruitment to telomeres using immunofluorescence-fluorescence in situ hybridization.  
TPP1 foci (green) were detected by immunofluorescence. Telomerase RNA (TR; red) 
was detected by fluorescence in situ hybridization. Yellow/orange coloration in the 
Merge panels signifies recruitment of TR foci to telomeres. (B) Quantitation of 
telomerase recruitment data of which panel A is representative.  The mean percentage 
of TR foci containing TPP1 foci was calculated and standard deviation for triplicate 




Figure 3.5 Several mutations in The TEN domain are permissive towards 
telomerase recruitment to telomeres. 
Stable HeLa-EM2-11ht clones overexpressing FLAG-TPP1, and transiently transfected 
with TR and the indicated TERT mutant were analyzed for telomerase recruitment to 
telomeres using immunofluorescence-fluorescence in situ hybridization.  TPP1 foci 
(green) were detected by immunofluorescence. Telomerase RNA (TR; red) was 
detected by fluorescence in situ hybridization. Yellow/orange coloration in the Merge 
panels signifies recruitment of TR foci to telomeres. Quantitation of telomerase 





Figure 3.6 Several mutations in the IFD affect recruitment of telomerase to 
telomeres. 
(A) Stable HeLa-EM2-11ht clones overexpressing FLAG-TPP1 and transiently 
transfected with TR and the indicated TERT mutant were analyzed for telomerase 
recruitment to telomeres using immunofluorescence-fluorescence in situ hybridization.  
TPP1 foci (green) were detected by immunofluorescence. Telomerase RNA (TR; red) 
was detected by fluorescence in situ hybridization. Yellow/orange coloration in the 
Merge panels signifies recruitment of TR foci to telomeres. (B) Quantitation of 
telomerase recruitment data of which panel A is representative.  The mean percentage 
of TR foci containing TPP1 foci was calculated and standard deviation for triplicate 
measurements (>100 TR foci scored in total) were plotted. (C) Immunoblot of the 





Figure 3.7 Several mutations in The IFD are permissive towards telomerase 
recruitment to telomeres. 
Stable HeLa-EM2-11ht clones overexpressing FLAG-TPP1 and transiently transfected 
with TR and the indicated TERT mutant were analyzed for telomerase recruitment to 
telomeres using immunofluorescence-fluorescence in situ hybridization.  TPP1 foci 
(green) were detected by immunofluorescence. Telomerase RNA (TR; red) was 
detected by fluorescence in situ hybridization. Yellow/orange coloration in the Merge 
panels signifies recruitment of TR foci to telomeres. Quantitation of telomerase 
recruitment data of which panel A is representative is shown to the right.  The mean 





Figure 3.8 Analysis of telomerase assembly of mutants in the TEN domain.  
HeLa cells were transiently transfected with TR and the indicated FLAG-TERT 
constructs and assembly was analyzed using immunofluorescence-fluorescence in situ 
hybridization. “-TERT“ implies cells were not transfected with TERT. TERT foci (green) 
were detected by immunofluorescence. Telomerase RNA (TR; red) foci were detected 
by fluorescence in situ hybridization. Yellow/orange coloration in the Merge panels 
signifies colocalization of TERT and TR. Quantitation of telomerase assembly data of 
which images are representative is shown to the right.  The mean percentage of TR foci 





Figure 3.9 Analysis of telomerase assembly of mutants in the IFD. 
HeLa cells were transiently transfected with TR and the indicated FLAG-TERT 
constructs assembly was tested using immunofluorescence-fluorescence in situ 
hybridization. TERT foci (green) were detected by immunofluorescence. Telomerase 
RNA (TR; red) foci were detected by fluorescence in situ hybridization. Yellow/orange 
coloration in the Merge panels signifies colocalization of TERT and TR. Quantitation of 
telomerase assembly data of which images are representative is shown to the right.  
The mean percentage of TR foci containing TERT foci was calculated (>50 TR foci 




Figure 3.10 Several mutations in the TEN domain and IFD affect telomerase repeat 
addition processivity. 
(A) Direct primer extension assay using primer a5. Lanes positive for POT1-TPP1 
contain 500 nM each of purified TPP1-N and POT1. (B) Quantification of direct primer 
extension assays. n = 3 for WT, K78E, N125A, T128I, and E793A/Q794A. n = 2 for 
L139A and L805A/F806A; average values are shown. p-values were calculated using a 
two tailed student’s t-test.  
 96 
 
Figure 3.11 Mutations in the TEN domain and IFD compromise telomeric repeat 
synthesis in vivo. 
A HeLa cell line that stably expressed FLAG-TPP1 was transiently transfected with the 
indicated TERT constructs and mutant TR that contains a non-telomeric template 
sequence. Immunofluorescence-fluorescence in situ hybridization was used to visualize 
newly synthesized mutant telomeric repeats. Channels detecting DAP1 (blue), FLAG-
TPP1 (green), newly synthesized telomeres (red), and TR foci (cyan) are shown. Merge 
panel illustrates an overlay of mutant telomere and TR panels. Non-specific binding of 
the mutant telomere probe to RNA in the nucleolus occurred in all cells (even in the 




Figure 3.12 Quantitation of cells that contain mutant telomeres. 
Quantitation of images for which figure 3.10 is representative. For each experiment >50 
cells were counted and the mean percentage of cells with foci containing both TR and 
mutant telomere sequence is shown for triplicate measurements. p-values were 




Figure 3.13 Two regions on TERT are predicted to interact with TPP1. 
Homology model of human telomerase (SWISS-MODEL) using the alignment in Figure 
3.2 along with the cryo-EM structure of Tetrahymena telomerase (PDB ID: 6D6V).  The 
solved crystal structure of the OB domain of TPP1 (PDB ID: 2I46) is shown in green. 
TEL patch residues are shown in red and NOB region residues are shown in orange. 
The IFD is shown in purple and the TEN domain in cyan. The regions in TEN and IFD 









 Throughout this dissertation the mechanisms by which telomeres and telomerase 
are able to work together to solve the end protection and end replication were discussed 
in detail (Chapter 1). The structural and functional consequences of a dyskeratosis 
congenita associated mutation in the shelterin component TPP1 were elucidated 
(Chapter 2). Two regions on TERT important for the recruitment of telomerase to the 
telomere were defined (Chapter 3). This Chapter is centered on a brief discussion of the 
conclusions we can draw from the studies presented here, questions that still remain, 
and the future directions for research on these topics. 
4.2 The dichotomous roles of POT1-TPP1 
 As discussed in Chapter 1, POT1 and TPP1 play two essential roles at 
telomeres. First, TPP1 is able to recruit POT1 to the single stranded portion of the 
telomere through its POT1 binding domain. Once there, POT1 protects single stranded 
telomeric DNA from being misrecognized by ATR mediated DNA damage response 
proteins by binding the DNA with high affinity and specificity (Kd~ 10 nM) [49,1,64]. 
Biochemical experiments have shown that TPP1 helps increase the affinity of POT1 for 
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single stranded DNA by about tenfold [64]. The POT1-TPP1 heterodimer also works to 
recruit telomerase and stimulate repeat addition processivity [64]. So it must allow 
telomerase to access the same end that it is actively protecting. How the complex is 
able to achieve these seemingly opposing roles is a question that still remains. 
Structurally what is known about this complex largely comes from small angle X-ray 
scattering (SAXS) data that depicts the TPP1-POT1-DNA complex forming a V-shape 
with the OB domain placed away from the 3’ end of the telomeric DNA [56]. This model 
does not agree with the solved structure of the POT1-TPP1 homolog from Sterkiella 
nova TEBP-α-β-DNA complex which forms a heart shape with TPP1 homolog TEBP-β 
interacting with the 3’ end of the DNA [48]. Future work is necessary to determine how 
the full POT1-TPP1 complex is able to bind telomeric DNA and how POT1 orients the 
OB domain to recruit telomerase (discussed in appendix A). The mechanism by which 
POT1 allows telomerase access has been investigated by single molecule FRET 
studies which have suggested that POT1-TPP1 may slide on the DNA allowing 
telomerase access [141]. Others hypothesize that during S-phase, telomeres may 
become more accessible to telomerase due to reorganization of shelterin [142]. With the 
publication of a cryo-EM structure of human telomerase future work should be directed 
at improving on the current structure by including POT1, TPP1, and other shelterin 
components along with a telomeric DNA substrate. This would provide a clearer picture 
of how shelterin occupies chromosome ends while allowing telomerase access to that 
same end. These cryo-EM studies would also help understand how POT1 is able to 
orient TPP1 to recruit telomerase.  
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4.3 Telomerase recruitment  
It is evident from our study presented in Chapter 2 that telomerase recruitment 
to, and subsequent action at, telomeres is essential for the continued renewal of vital 
cell populations like hematopoietic stem cells. In stark contrast, it is known that aberrant 
telomerase activation in somatic cell populations allows cancer cells to maintain their 
telomeres, leading to replicative immortality, a hallmark of cancer. Because recruitment 
is one of the major steps in both of these scenarios, the telomerase-telomere interface 
is an attractive target for therapeutics.  
4.3.1 The role of TPP1 in telomerase recruitment  
In Chapter 2 I demonstrated how a previously discovered mutation in the 
telomeric protein TPP1 caused telomere shortening and the telomeropathy dyskeratosis 
congenita in a patient. The TEL patch and the recently discovered NOB regions of 
TPP1 were shown to be imperative to telomerase recruitment to the telomere, 
suggesting that mutations in these regions would cause telomerase deficiency diseases 
such as dyskeratosis congenita [69,66,68]. Indeed, we showed that an in-frame deletion 
of lysine 170 found in the TEL patch loop displaced the C-α backbone of two critical 
glutamates causing telomere shortening and telomeropathies in two unrelated patients. 
We were able to use CRISPR-Cas9 gene editing to introduce this mutation into HEK 
293T cells in a heterozygous context to show that this mutation caused the telomere 
shortening seen in the patient. Our genetic analysis revealed that the dosage of a 
functional TEL patch was important for telomerase to maintain telomeres as a cell line 
with only one copy of WT TPP1 shortened at a faster rate than a cell line with one copy 
each of K170Δ and WT TPP1. Our study encourages the use of small molecules to 
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rescue the TPP1-telomerase interaction. Reestablishing this interaction with a small 
molecule could help facilitate telomere length maintenance in stem cell pools throughout 
the body.  Alternatively our study also suggests gene therapy could be used to correct 
mutations in TPP1 to treat patients with TPP1 TEL patch mutations, as currently bone 
marrow transplant is the only disease management option for these individuals. 
4.3.2 Regions on the TEN domain and the IFD are involved in telomerase 
recruitment 
In Chapter 3 I designed an alanine scanning mutagenesis screen to discover 
what residues on the TEN domain and IFD are important for telomerase recruitment to 
the telomere. I used the recently published high resolution structure of Tetrahymena 
telomerase along with my sequence alignment to make a homology model of human 
telomerase [121]. The residues I found to be important on the TEN domain span two 
helices connected by a short linker. These helices are facing the OB domain of TPP1 in 
our model and are in close proximity to the TEL patch loop that contains three critical 
glutamates (E168, E169, and E171). This region seems to be structurally conserved as 
it is not only helical in the Tetrahymena TEN domain crystal structure, but is also shown 
to be helical in the crystal structure of the TEN domain of Hansenula polymorpha TERT 
[100,99]. The region I found to be important in the IFD begins in what is predicted to be 
a flexible linker in our homology model, but is part of a β-sheet that continues into a 
short linker region in the homologous Tetrahymena structure. In both scenarios the β-
sheet continues in to a C-terminal helix that has residues that both face the TPP1 OB 
domain and interact with an N-terminal helix of the IFD. The IFD is in close proximity to 
the NOB region of TPP1, and I would predict that the two to interact. Together, both of 
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these stretches of residues are predicted to form one surface that interacts with the OB 
domain of TPP1, while the previously identified K78 residue is just outside of this 
surface, but still in close proximity to its biochemically identified binding partner, E215 of 
the TEL patch. In the future we plan to crystallize the OB domain in complex with 
peptides from the regions in the TEN domain and IFD that I identified in my alanine 
scanning mutagenesis screen. If the IFD does indeed bind the N-terminus of TPP1, I 
would expect the OB domain to crystallize in a different lattice than it does alone, as it 
uses its N-terminus to make a non-physiological dimer in the asymmetric unit of the 
apo-OB domain structure. A high resolution crystal structure of the OB domain of TPP1 
in complex with a peptide of the TEN domain, IFD, or a combination of the two would 
allow us to uncover the atomic details of the interaction. This would inspire the search 
for small molecules to target this interface as it could be another potential target for a 
variety of cancers (see below). Ultimately, to follow up the cryo-EM characterization of 
human telomerase, future studies should attempt to use TPP1, the POT1-TPP1 
complex, or the complete shelterin complex, to uncover the full atomic details of the 
telomerase-telomere interface. 
4.3.3 Targeting telomerase recruitment for anti-cancer purposes 
It can be argued that an anti-telomerase recruitment drug would also shorten 
telomeres in stem cells. However, it is known that most stem cell populations have 
much longer telomeres than cancer cells, which are typically operating barely above the 
critical threshold of telomere length required for continued proliferation. Therefore a 
drug that causes telomere shortening will likely push cancer cell telomeres below the 






A.1 Introduction  
 The POT1-TPP1 heterodimer aids in maintaining chromosome ends by both 
protecting them and recruiting telomerase to synthesize telomeric repeats. POT1 
protects chromosome ends from being misrecognized as a DNA lesion by excluding 
DNA damage response machinery from the chromosome end [1]. It carries out this 
function using two N-terminal OB domains that bind single stranded telomeric DNA 
(specifically the TTAGGGTTAG sequence) with high affinity and specificity [13]. This 
same sequence is the substrate for telomerase catalysis. Given this, it is not surprising 
that POT1 binding to a telomeric primer inhibits telomerase activity in vitro. POT1 binds 
with 10-fold higher affinity (reducing the kD from 10 nM to 1 nM) when associated with 
its binding partner, TPP1 [64]. Thus one would predict the POT1-TPP1 to be an inhibitor 
of telomerase, but in sharp contrast POT1-TPP1 increases the activity and processivity 
of telomerase. How binding of TPP1 to POT1 switches POT1 from being an inhibitor of 
                                            
4
 The work in this chapter was performed in collaboration with Dr. Valerie Tesmer. Valerie performed the 
EMSAs in Figure A.2.Both Valerie and I independently expressed and purified the TPP1-POT1-DNA 
protein complexes and attempted crystallography. I expressed and purified all TPP1-N mutants and 
performed all experiments with those mutants. The OB-DBD crystals were initially obtained by Valerie 
Tesmer. Attempts at phasing were performed in collaboration. Valerie designed and performed 
experiments with the BrdU containing oligomers. Jayakrishnan Nandakumar, Valerie Tesmer, and I 
attempted data collection. We independently processed data of a variety of OB-DBD crystals that were 
obtained. 
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telomerase to a stimulator of this enzyme is still poorly understood.  Given these 
dichotomous roles it is unclear how POT1 and TPP1 work together to both protect 
chromosome ends and allow telomerase access to that same end to facilitate end 
replication. To address this question, I describe in this Section my ongoing work to 
elucidate the structure of the POT1-TPP1 heterodimer in complex with DNA.  
A.2 Results 
A.2.1 TPP1-POT1-DNA complex formation 
Prior to TPP1-POT1-DNA complex formation several experiments were carried 
out to determine the optimal DNA substrate and TPP1 constructs to use in our 
crystallography trials. C-terminal truncations of TPP1 were engineered based on the 
results of limited proteolysis experiments. TPP1 is made up of an N-terminal OB domain 
that is responsible for recruiting telomerase, a central POT1 binding domain, and a C-
terminal TIN2 binding domain (Figure  A.1A). Here we utilize a truncated version of 
TPP1, which eliminates the TIN2 binding domain, but contains the N-terminal OB 
domain and POT1 binding domain. We expressed and purified TPP1 (87-337) from high   
five insect cells. After five minutes of digestion with chymotrypsin, TPP1 (87-337) 
degrades into a band that migrates near 22 kD (Figure A.1B). After ten minutes this 
further degrades into what we suspect is the OB domain of TPP1 which is 
approximately 18 kD. Upon inspection of the TPP1 sequence, constructs ending at 
amino acids 300 and 287 were engineered with (87-287) being the most stable TPP1 
construct (Figure A.1B). We also performed crystallization trials with POT1 constructs 
that lacked the DNA binding domain (POT1 299-634 and POT1 334-634) (Table A.1). 
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We were also able to express, purify, and attempt crystallization of mouse TPP1-
POT1a-DNA (Table A.1). 
To determine the optimal DNA for crystallization trials we performed a series of 
electrophoretic mobility shift assays (EMSA). In these experiments we tested the ability 
of TPP1-POT1 to bind a variety of telomeric oligomers (Figure A.2A). The oligomers 
were designed based on the solved crystal structure of the POT1 DBD. We found that 
the POT1-TPP1 heterodimer bound oligomers with two (SS3 and SS8) or three (SS4) 5’ 
guanosines with higher affinity than constructs with one 5’ guanosine or a 5’ thymidine 
(Figure A.2B). The DNA oligomers SS3, SS4, and SS8 were used in crystallization trials 
described below. 
A.2.2 TPP1-POT1-DNA crystallography 
After determining which DNAs, POT1, and TPP1 constructs to use for 
crystallography, we began forming TPP1-POT1-DNA complexes using size exclusion 
chromatography (Figure A.3A and B). The ratio of absorbance at 260 nm and at 280 nm 
was used to confirm that the complex contained DNA. Once these complexes were 
concentrated to suitable amounts for crystallography (~10 mg/ml), trays were set using 
either an Oryx 8 crystallography robot (sitting drop) or by hand in a 24 well format 
(hanging drop) at 20 °C, 16 ° C, and 4° C.  The combinations of proteins and DNAs 
screened can be found in table A.2. We screened for conditions that yielded crystals 
with a homemade PEG screen and ammonium sulfate screen along with the Qiagen 
PEG suite, Qiagen Classics suite, and Qiagen JCSG+ suite. Crystals of TPP1(87-334)-
POT1-SS3 were obtained with 28% PEG 4000, 0.2 M Li2SO4, 0.1 M Tris (pH 8.5) 
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(Figure A.4). These crystals were cryoprotected and data was collected at the APS 
beamline. The diffraction pattern yielded very few spots at low resolution. 
A.2.3 Mapping the TPP1-POT1 binding interface 
 Concurrent with our attempts to elucidate the structure of the TPP1-POT1-DNA 
complex, we biochemically characterized the interface between these two proteins. To 
do this we employed a scanning alanine mutagenesis screen, where we mutated 
residues in the previously identified POT1 binding domain of TPP1 (PDB). We 
engineered 14 mutants in total, two single mutants and twelve double mutants, which 
spanned the PBD of TPP1. Using sequence conservation and the TEBP-α-β structure 
as guides, we mutated conserved residues predicted to be on the surface of the human 
PBD. All mutants were expressed as C-terminal truncated TPP1 constructs, called 
TPP1-N (87-334) that lacked the C-terminal TIN2 binding domain. Initially we expressed 
and purified these constructs in E. coli (Table A.1). Several constructs expressed and 
concentrated as well as wild type (1-3 mg from 3 L of culture), but T286A and 
T291A/W293A both showed sizeable protein loss during concentration (1-2 mg). After 
expressing and purifying all constructs, I was able to perform a chymotrypsin digest to 
determine which constructs were correctly folded (Figure A.5). We found that both TPP1 
T286A and TPP1 T291A/W293A both had digest patterns that did not match that of wild 
type. This data along with the difficulty in concentrating both proteins during purification 
suggests that the proteins are not well folded. After determining that a majority of the 
mutations did not grossly affect TPP1 protein folding we set out to test the ability of 
these proteins to interact with POT1. To this end we performed a fluorescence-based 
quantitative binding assay. This assay involves the immobilization of POT1 on beads 
 108 
using biotin-streptavidin chemistry and the labeling of TPP1 with fluorophores using 
thiol-reactive reagents. We incubated the POT1 with fluorescently labeled wild type 
TPP1 and titrated in unlabeled WT and mutant proteins to displace the previously bound 
fluorescently labeled WT TPP1 protein. We found that TPP1 S255A/L257A, 
L271A/L274A, T291A/W293A, Y306A/V308A, L313A/I315A, and L323A were all 
defective relative to (unlabeled) WT in displacing Alexa Fluor labeled WT TPP1 from 
POT1 (Figure A.6). While mutants S255A/L257A and L271A/L274A were tested in 
triplicate, the other mutants were tested in only a single experiment. During the course 
of these experiments two separate labs solved structures of the PBD of TPP1 in 
complex with the third OB domain of POT1 that also contained a Holliday junction 
resolvase like domain insertion, providing high resolution atomic details of this interface 
(Figure A.7) [56,57].  Both structures were in agreement with the interface mutants we 
identified in our screen. 
A.2.4 OB-DBD crystallographic studies 
Due to our inability to obtain TPP1-POT1-DNA crystals with full length POT1 and 
TPP1-N constructs, we employed an alternative approach to try to understand how 
POT1 orients the TPP1 OB domain for telomerase recruitment and putative DNA 
binding. In this approach we utilized a 20 amino acid serine/glycine linker to connect 
TPP1’s OB domain with POT1’s DBD. Although previous biochemical data has not 
detected an interaction between these two domains, we hypothesized that the POT1 
DBD influences how TPP1’s OB domain is oriented with respect to the 3’ end of the 
telomeric DNA. Additionally both of these domains have been previously crystalized 
individually, but not in the presence of the other. Published work from the lab has 
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demonstrated that this tethered OB-DBD construct is able to stimulate telomerase 
activity and processivity to the same extent as the POT1-TPP1-N heterodimer [69]. This 
suggests that POT1 simply acts as an anchor for the OB domain of TPP1, aiding it in 
recruiting telomerase by ensuring its placement at the end of telomeric DNA. To gain a 
better understanding of how POT1-DBD is able to help orient the OB domain of TPP1 
and to identify putative residues that interact between the two domains we set out to 
crystallize an OB-DBD-DNA complex. After expressing and purifying the fusion protein 
from E. coli we obtained crystals from two different conditions. Both conditions 
contained 20% PEG 6000, 0.1 M Sodium Citrate (pH 5.0), but differed in having either 
0.1 M LiCl or 0.2 M Li2SO4 (Figure A.8). The crystals were cryoprotected by introducing 
20% ethylene glycol into the crystallization conditions. Crystals from the LiCl conditions 
diffracted to a resolution of 3.1 Å, while the crystals from the Li2SO4 conditions diffracted 
to 2.7 Å. Upon data processing the LiCl crystals indexed to I121 (a= 81.75 b= 48.20 c= 
114.44 α= 90 β= 94.90 γ= 90) (Table A.3). Molecular replacement was attempted using 
several truncated versions of TPP1 OB and POT1 DBD, but Phaser [143,144] often 
found greater than 20 solutions with low z-scores and the highest scored solutions were 
unable to be refined. Upon data processing the Li2SO4 crystals indexed to P1211 (a= 
48.23 b= 140.5 c= 72.62 α= 90 β= 99.27 γ= 90). Molecular replacement was attempted 
with Phaser using various combinations and truncated versions of the TPP1 OB domain 
and DBD as the search models (100% sequence similarity), but no reasonable solutions 
were obtained. Data were collected from additional crystals grown in Li2SO4 and 
processed. Initially these data processed to C121 (a= 116.39 b=116.39 c= 162.27 α= 90 
β= 90 γ= 90), but Xtriage indicated that there was a significant twin fraction, even 
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though the intensity statistics did not suggest twinning. The symmetry operators 
predicted a higher order space group P4122/P4322 (a= 82.42 b= 82.40 c= 162.56 α= 90  
β=90 γ=90) (Table A.4). After the data was reprocessed to P4122 the phasing of the 
data was attempted by molecular replacement using Phaser with various combinations 
of the TPP1 OB domain and POT1 DBD as the search models (100% sequence 
similarity). The enantiomeric space group P4322 was also tested in molecular 
replacement. Matthews coefficient determination suggested that the asymmetric unit 
contained one copy each of the TPP1 OB domain and the POT1 DBD (made up of two 
OB domains). Attempts at molecular replacement with TPP1 or POT1 OB domains 
yielded MR solutions with unimpressive z-scores that did not improve substantially upon 
placement of additional OB domains. These solutions did not improve upon refinement 
as indicated by the fact the RFree was consistently above 0.5 regardless of how many (of 
the three) OB domains were present in the solution.  
After multiple iterations of molecular replacement with varying combinations of 
truncated search models we attempted to phase the crystals de novo. We took three 
separate approaches to do this: heavy metal soaks, selenomethionine incorporation, 
and brominated DNA. Crystals grown in LiCl and Li2SO4 conditions were soaked in 50 
mM thimerosal for either 1 h or overnight (~16 h).  Crystals grown in both conditions 
were also soaked for 5 min or 10 min in one of the following: mercury (II) acetate (10 
mM or 1 mM), platinum (IV) chloride (10 mM or 50 mM), potassium tetrachloroplatinate 
(II) (50 mM), gold chloride (10 mM or 50 mM), and sodium tetrachloroaurate (10 mM or 
50 mM). A crystal grown in Li2SO4 and soaked overnight in 50 mM thimerosal did 
diffract to 3.5 Å, but only had weak anomalous signal to 6.9 Å. LiCl crystals soaked in 
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mercury (II) acetate diffracted to 3.1 Å, but only had weak anomalous signal that 
extended to 5.8 Å and had low completeness (<50%). Due to the fact that heavy metal 
soaks didn’t yield any useful datasets that could be used to phase our crystals we next 
attempted selenomethionine incorporation into the protein. Although the OB domain of 
TPP1 (90-250) doesn’t contain any methionines, the DBD of POT1 contains five. The 
fusion protein was expressed in an auxotrophic strain of E. coli with selenomethionine 
supplemented media. Crystals formed in 23-25% PEG 6000, 0.2 M Li2SO4, and either 
0.1 M Bis-Tris (pH 5.5) or 0.1 M MES (pH 6.0). The crystals were harvested and 
cryoprotected by introducing 20% ethylene glycol in the crystallization conditions.  Many 
crystals grown under these conditions failed to diffract or diffracted very poorly. Crystals 
that diffracted well also failed to yield any significant anomalous signal although the 
fluorescence scan indicated the presence of selenium. Finally, we complexed the OB-
DBD construct with two different BrdU incorporated DNA oligomers [5’-
(BrdU)GGTTAGGGTTAG-3’ and 5’-(BrdU)GGTTAGGG(BrdU)TAG-3’]. We obtained 
crystals in 23-28% PEG 6000, 0.2 M Li2SO4, 0.1 M sodium citrate (pH 5.5). Upon 
harvesting, the crystals were cryoprotected with 20% ethylene glycol.  Although many 
crystals diffracted well (~3 Å) we failed to detect any significant anomalous signal. In the 
future we plan to continue to try to phase the crystals by trying alternative heavy metals 
and attempting to collect data on more crystals with BrdU incorporated DNA. 
A.3 Materials and methods 
A.3.1 Plasmid constructs 
The pET-Smt3-TPP1-N plasmid for expression and purification of human TPP1-N was 
described previously. Full length POT1 was cloned into the pFASTBAC HTB vector 
 112 
using restriction cloning. Site directed mutagenesis was carried out to introduce 
mutations in TPP1 and POT1-expression plasmids. These mutations were introduced 
with mutagenic primers (Integrated DNA Technologies) using the QuikChange® Site-
Directed Mutagenesis Kit (Agilent Technologies). The TPP1 and POT1 sequences in 
the mutant plasmids were sequenced using Sanger sequencing to confirm both the 
presence of the intended mutation and the absence of unwanted errors introduced 
during PCR amplification/cloning 
A.3.2 Protein expression and purification 
WT and mutant constructs of Smt3-TPP1-N and TPP1 OB-POT1 DBD proteins were 
obtained upon purification from lysates of BL21(DE3) cells induced with isopropyl β-d-
thiogalactopyranoside as described previously [127,69]. Lysate obtained from these 
cells was first passed over a Nickel-agarose column, and once the protein was eluted it 
was treated with Ulp1 protease (MTA with Cornell University for pUlp1 vector) to cleave 
the Smt3 tag. Size-exclusion chromatography (Superdex 75; GE Life Sciences) was 
performed as the final step of protein purification.  The His-Sumostar-hPOT1 baculoviral 
expression plasmid described previously was used to express full-length POT1 in 
baculovirus-infected High Five cells (Life Technologies) using vendor recommendations 
[127].  Sumostar-POT1 fusion protein was purified from insect cell lysates by passing 
the lysate over a nickel-agarose column. After elution the tag was cleaved with 
SUMOstar protease (Life Sensors) and the POT1 protein was further purified by anion 
exchange (HiTrap Q HP; GE Life Sciences), and size-exclusion chromatography 
(Superdex 200; GE Life Sciences). All protein-DNA complexes, including ones with 
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BrdU incorporation were formed by mixing proteins/DNA prior (2:1 molar ratio of DNA to 
protein) prior to injection onto a size-exclusion column (S200). 
A.3.3 Chymotrypsin proteolysis experiments 
Initially all concentrations of proteins were determined by protein assay reagent (Bio-
Rad). Chymotrypsin (Promega; V160) was dissolved at 1 mg/ml in 50 mM Tris (pH 8.0), 
50 mM NaCl, 2 mM CaCl2. 16 µl digestion reactions were carried out a ratio of 1:62.5 of 
chymotrypsin to protein. 4 µl of reaction was removed at the indicated time and mixed 
with 4 µl of 2X SDS-loading dye and heated at 90 °C for 10 min before being loaded on 
an 10% SDS-PAGE gel. 
A.3.4 Electrophoretic Mobility Shift Assays 
Each telomeric DNA oligomer was 5’ labeled with 32P using T4 PNK (New England 
Biolabs). The reaction was performed with [γ-32P] ATP, 10 units PNK, and 2 µM primer 
in 1X PNK buffer, 8 mM Tris (pH 8.0), 5 mM DTT for 30 min at 37 °C. After the reaction 
28 µl of Tris (pH 8.0) was added and to quench the reaction EDTA was added to a final 
concentration of 10 mM and the reaction was heated to 65°C for five min. To get rid of 
unincorporated radiolabel the reaction was passed through a Quick Spin Protein 
Column (Rouche, G25 Sephadex). The EMSA was performed in a 10 µl binding 
reaction which contained 1 µM of each cold DNA oligomer and trace amounts of the 32P 
labeled DNA oligomer (described above). The DNA oligomers were diluted in 50 mM 
Tris (pH 8.0), 6% glycerol, and 80 mM NaCl. A 4 µM POT1-TPP1(87-337) stock was 
made in the same buffer the DNA oligomers were diluted in. Then the proteins were 
serial diluted to 400 nM, 200 nM, 100 nM, and 50 nM. The binding reactions were then 
electrophoresed on a 6% acrylamide-bisacrylamide-0.5X TBE gel. The gel was pre-run 
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for 30 min at 100 V before the samples were loaded and the gel was run for 45 min at 
100 V. After being run the gel was vacuum dried for 1 h at 80 °C. The radioactive signal 
was detected by exposure to a phosphorimager screen and by imaging on a storm 
phosphorimager. 
A.3.5 Flow cytometry based protein-protein binding assays 
Labeling reactions: Initially, proteins were labeled with either biotin or a fluorophore as 
described previously [145,146]. Briefly, proteins were passed through a Micro Bio-spin 6 
spin column (Bio-Rad) to remove DTT. The concentrations of the proteins were 
calculated using the Protein Assay Reagent (Bio-Rad). To label TPP1 with a 
fluorophore and POT1 with biotin we used a 2:1 mole ratio of Alexafluor488-C5-
maleimide (Life technologies) to TPP1 or a 2:1 mole ratio of biotin maleimide (Sigma; 
B1267) to POT1. Each reaction was allowed to proceed for 20 min at room temperature 
and then passed through a second spin column to remove any unreacted label. 
Competition experiments: 24 µl of uniformly-sized streptavidin beads (Spherotech; SCP-
20-5) were washed three times with 200 µl of flow buffer (20 mM Tris (pH 8.0), 100 mM 
NaCl, 2 mM DTT, 1% bovine serum albumin, and 0.1% lubrol). The beads were then 
resuspended in 320 µl of flow buffer. Biotin labeled POT1 was added to the beads at a 
final concentration of 150 nM and was incubated with the beads on ice for 1 h. After 1 h 
the beads were washed three times with flow buffer to remove unbound POT1. Then 
100 nM of Alexa Fluor labeled WT TPP1 was incubated with the beads. The unlabeled 
mutant TPP1 constructs were serial diluted in flow buffer in a 96 well plate (400 nM – 
2.125 nM final concentration). The beads containing biotin POT1 and Alexa Fluor 
labeled TPP1 were added to each well and left to incubate on ice for 4 h. After 
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incubation on ice samples were loaded on an Accuri C6 flow cytometer (BD 
biosciences) using a Hypercyt autosampler (IntelliCyt). The median fluorescence 
intensity on the beads for technical duplicates which were performed on the same plate 
was calculated using the Hypercyt software. Median fluorescence values were fit to a 
one-site competition curve in Prism 7.0 (GraphPad). 
A.3.6 Crystallography experiments 
After purification all proteins crystal trays were set either using an Oryx 8 
crystallography robot or by hand. When crystal trials were set with the robot, 50 µl of 
each screen solution was pipetted by hand into the wells of an MRC 2 Lens 
Crystallization Microplate (MRC96T-UVP). Screens used include: Qiagen PEG suite 
(Qiagen; 130704), Qiagen Classics Suite (Qiagen; 130701), Qiagen MPD Suite 
(Qiagen; 130706), and NeXtal JCSG+ Suite (Qiagen; 130720). The robot then pipetted 
0.5 µl of the well solution and 0.5 µl of the protein as a sitting drop. To optimize 
conditions with potential crystal hits additional screens were set by hand using 24 well 
plates (hanging drop). All crystal trays were kept in incubators (16°C or 20°C) or in a 
cold room (4°C). Crystals were cryoprotected as reported in the results section and X-
ray diffraction data were obtained at the Life Sciences Collaborative Access Team (LS-
CAT) beam line 21-ID-D of the Advanced Photon Source. The data for BrdU containing 
crystals was collected at 13.5 keV and the data for SeMet containing crystals was 
collected at 12.7 keV. Data sets were processed by iMosflm (CCP4) or Dials (CCP4). 
Scaling and merging were performed using Aimless (CCP4) and Pointless (CCP4). In 
addition to manual inspection of the data, Xtriage (Phenix) was used to aid in 
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determining the quality of the data. Molecular replacement was performed in Phaser 






A.4 Figures and Tables 
 
Figure A.1 Determining stable constructs of TPP1. 
(A) Domain diagrams of TPP1 and POT1. PBD stands for POT1 binding domain. HJRL 
stands for Holliday junction resolvase like domain. (B) Coomassie-blue stained SDS-
PAGE gel of various TPP1 constructs incubated with chymotrypsin for the indicated 





Figure A.2 Affinity of TPP1-POT1 for telomeric DNA oligomers. 
(A) The composition of the single stranded DNA oligomers used in EMSA assays and 
crystallization studies. Purple shows the telomeric DNA sequence that the POT1 DBD 
was crystallized with. (B) Electrophoretic mobility shift assays (EMSA) measuring the 
affinity of POT1-TPP1 for telomeric DNA oligomers. Binding reactions were performed 
either without TPP1-POT1 (- lane) or with increasing amounts of TPP1-POT1 complex 




Figure A.3 Purification of a TPP1-POT1-DNA complex. 
(A) Representative chromatogram from the isolation of the TPP1-POT1-DNA complex 
after purification by size exclusion chromatography (S75 column). The absorbance at 
280 nm is shown in blue and the absorbance at 254 nm is shown in red. (B) Coomassie 





Figure A.4 TPP1-POT1-DNA crystallography.  





Figure A.5 Analysis of protein stability by limited proteolysis. 
Time course analysis by SDS-PAGE of the chymotrypsin digest of the indicated TPP1-N 
constructs. Samples were taken from the reaction at the specified times. TPP1-N runs 





Figure A.6 Biochemical analysis of the POT1-TPP1 binding interface. 
Fluorescence-based competition experiments using Alexa Fluor labeled WT TPP1-N 
bound to biotin labeled POT1 on streptavidin beads titrated with varying amounts of the 
unlabeled mutant or WT TPP1-N constructs. The mean of a technical duplicate 
performed on the same plate is plotted for each experiment. Mutants H214A/L242A, 
S245A/S248A, L252A/L254A, and S255A/L257A were assayed in triplicate. All others 
were tested as technical duplicates in a single experiment. Error bars represent 
standard deviation of technical duplicates. 
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Figure A.7 Mapping biochemically identified residues onto the structure of POT1-
TPP1. 
Solved crystal structure of the third OB domain of POT1 (forest green) and the Holliday 
junction resolvase like domain (HJRL) of POT1 (lime green) in complex with the TPP1 
POT1 binding domain (PBD) (Blue) (PDB ID: 5H65 and 5UN7). Residues that were 
found to be important in our alanine mutagenesis screen are shown as sticks in red.  
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Figure A.8 Crystals of TPP1 OB-POT1 DBD fusion in complex with telomeric DNA. 
Photographs of crystals of TPP1 OB linked to the DBD of POT1 with a 20 amino acid 
long serine/glycine linker grown in hanging drops at 20°C.  
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